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Abstract
Role of dorsomedial prefrontal cortex astrocytes in mouse 
dominance and depressive behavior
Kyungchul Noh
Program in Neuroscience
Department of Dental Science
The Graduate School of Seoul National University
Dominance behavior is a fundamental organizing mechanism for most 
animal societies. Achieving and remaining at a high social status are essential for 
survival. Recent studies have identified that pyramidal neurons in dorsomedial 
prefrontal cortex (dmPFC) region have a key role for remaining and maintaining at 
high social status. There is also a correlation between social status and mental 
health such as depression. In human, individuals with low socio-economic status 
(SES) are vulnerable to depression. Furthermore, astrocytes in dmPFC region are 
also involved in mouse depression and the response to anti-depressant drugs. Here, 
in this study, I suggest that dmPFC astrocytes in mice are directly involved in both 
dominance and depressive-like behaviors. 
In the first part of this thesis, I applied both chemogenetic and optogenetic 
manipulation of dmPFC astrocytes into low social ranked mice. Both chemogenetic 
and optogenetic stimulation of dmPFC astrocyte successfully induced hierarchical 
rank graduation of subordinate mice by showing resistance behavior rather than 
pushing behavior during social competition. Optogenetic stimulation of dmPFC 
astrocytes increased extracellular glutamate level leading to the increase of 
excitatory synaptic inputs into layer V pyramidal neurons. I next compared 
astrocyte stimulation-induced dominance behavior with the results of neuron 
stimulation, and both mouse groups showed comparable winning rates in the tube 
test with different behavioral mode to achieve dominancy.
ii
In the second part, I investigated the relationship between dominance 
behavior and depression. After 3 weeks of restraint stress (RS), the RS-received 
mice (RS mice) showed depressive-like behavior, and they also showed reduced 
dominance behavior compared with that of control mice. However, after
chemogenetic stimulation of dmPFC astrocyte into RS mice, they showed 
increased resistance behavior against control mice during the tube test, and RS 
mice started to push, which was not observed during the basal behavior. This 
behavioral shift may be due to the prior winning experience obtained by resistance 
action, which might confer a winning effect. Furthermore, repetitive winning 
experience abrogated depressive-like behavior of RS mice. However, neuron-
stimulated RS mice did not show anti-depressive behavior although they obtained 
winning experience by pushing action. This result suggests that rapid anti-
depressive effect can be obtained by astrocyte-derived winning experience in mice.
In conclusion, dmPFC astrocyte activation enhances mouse dominance 
behavior by persistent resistance behavior. Moreover, depressive-like phenotype 
shown in chronic RS mice can be rapidly reversed by repetitive winning experience. 
This result suggests that the association between dominancy and depression 
through dmPFC astrocyte activity provides a clinical implication in treating
depression due to low social status.
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Figure 11. Optogenetic stimulation of dmPFC astrocyte modulates social 
h i e r a r c h y  t h r o u g h  A M P A  r e c e p t o r  a c t i v a t i o n . 
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Figure 12. AMPA receptor antagonist, NBQX, does not induce hierarchical 
r a n k  e l e v a t i o n  o f  r a n k - 4  m i c e . 
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Figure 13. NBQX pretreatment in the dmPFC region does not alter 
l o c o m o t i o n ,  a n x i e t y ,  o r  d e p r e s s i v e - l i k e  b e h a v i o r . 
⸱⸱⸱⸱⸱⸱⸱⸱⸱⸱⸱⸱⸱⸱⸱⸱⸱⸱⸱⸱⸱⸱⸱⸱⸱⸱⸱⸱⸱ 5 2
Figure. 14. Astrocytes and neurons in dmPFC employ distinct behavioral 
s t r a t e g i e s t o  a c h i e v e  d o m i n a n c y  d u r i n g  t u b e  t e s t .
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F i g u r e  1 5 .  G r a p h i c a l  s u m m a r y  o f  t h e  s t u d y . 
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Chapter II. The effects of dmPFC astrocyte activation-induced 
dominancy on depression
Figure 1. Experimental schemes to measure winning-induced anti-
d e p r e s s i v e  e f f e c t . 
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Figure 2. Chronic restraint stress induces increased depressive-like 
b e h a v i o r s . 
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Figure 3. Behavioral mode shifts of RS mice by dmPFC astrocyte activation.
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Figure 4. Behavioral mode shifts of RS mice by dmPFC pyramidal neuron-




Figure 5. Winning experience with resistant behavioral strategy in the tube 
competition has a rapid anti-depressant-like effect on chronic restraint 
s t r e s s - i n d u c e d  d e p r e s s i o n . 
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Figure 6. dmPFC astrocyte activation-derived anti-depressive-like behaviors 
were not observed in the absence of tube test winning experiences. 
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Figure 7. Acute dmPFC astrocyte activation does not induce anti-depressant 
e f f e c t . 
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Figure 8. Astrocyte-derived winning experience has a 75% of anti-
d e p r e s s a n t  e f f e c t  i n  R S  m i c e . 
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Figure 9. Behaviors of RS mice after repetitive winning are classified as 
non-RS-l ike behaviors  by the K-means cluster ing analysi s .
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Figure 10. Astrocyte-induced winning renders rapid anti-depression. 
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1-1. Social hierarchy in human and animal
Human social status is prominent in different domestic, work, and 
recreational settings, where they define implicit expectations and actions that drive 
appropriate social behavior1. Furthermore, human social status predicts morbidity, 
survival, and even suicide2-4. A study has suggested an important role for 
hierarchical rank in achieving accurate self-knowledge and self-improvement, 
particularly in the usage of upward social comparisons5. Social hierarchies are 
usually emerged in children at age around 2 years1,2. Status within a social 
hierarchy is often made explicit, but can also be inferred from cues such as facial 
features, height, gender, and age6. In humans, dominance has been linked to 
heritable personality traits7, because dominancy is also considered as a feeling of 
control and influence over one’s surroundings or others versus feeling controlled or 
influenced by situations or others. Therefore, representing dominance behavior to 
reach high status in social hierarchy is an instinct behavior of human being.
Dominance behaviors can also be seen across various species of animal 
societies including fish8, rodents9,10, and monkeys11,12, making this an instinctive 
behavior evolutionally preserved across the animal kingdom. According to the 
mouse studies, group-housed mice show stable social hierarchy13,14. These studies 
indicate that activity of neural population in dorsomedial prefrontal cortex 
(dmPFC) is a key mechanism related with social competition and winning14. 
Optogenetic neural potentiation of mediodorsal thalamus (MDT) and dmPFC 
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circuit is involved in the winner effect. Furthermore, dominance relationship can be 
predicted by initial social interaction15. Interbrain correlation measured by 
microendoscopic Ca2+ imaging technique is occurred when the two mice interact 
with each other. Result indicated that dominant mice preferentially drives 
interbrain synchrony, therefore, social dominant relationship can be predicted15. 
Considering that both human and other animals are all social species, developing 
hierarchy is natural phenomenon, and furthermore, trying to be a high social status 
is innate behavior.
1-2. Social status and health
As dominance hierarchies exist in numerous social species, and rank in 
such hierarchies can dramatically influence on the quality of an individual’s life16, 
social status can strongly influence on the health of an individual particularly in 
stress-related diseases. One factor that is pervasively linked to mood disorder is 
socio-economic status (SES), which is the evidence that individuals with low SES 
are affected by mental health problems and their adverse consequences17,18. Meta-
analysis studies indicate that those of lower SES are at a higher risk of 
experiencing depression in their lifetime than those with high SES19,20. Low income, 
a gross marker of SES, has also been shown to be related to psychopathology, 
including suicidal ideation21,22. Indeed, although the absolute level of income is not 
a direct causal factor for mental health outcomes, however, the rank of income 
compared to others within a similar social group appears to be important23,24. These 
findings indicate that lower social status is associated with mental disorders.
４
The association between social hierarchy and mood disorders is also 
related with psychological feature such as emotion suppression25. Suppressing 
negative emotion has mental health cost, and individuals with low SES and low 
social status may use these strategies to avoid conflict25. It may be that it is not only 
the experience of negative emotion or lack of positive emotion that influences 
health, but the need to suppress the expression of emotion26,27. The experience of 
low social power and status unfolds in a social environment that may increase the 
need to suppress or inhibit one’s experience to the extent that others with more 
power can punish and threaten them28. Moreover, facial muscle actions associated 
with the suppression of emotion are more common among individuals with low 
status compared to those with high status29. The process of silencing the self in 
order to maintain harmony within a social relationship is a proposed mechanism for 
the prevalence of mental health. These self-silencing is associated with emotion 
such as depression across individual’s low SES in human.
Recent mouse studies suggested that dominant mice in social group 
exhibit aggressive behavior towards their cage mates and form a social 
hierarchy13,14. Dominant animals have different synaptic efficacies to subordinate 
animals13. Characteristic differences in gene expression in dominant and 
subordinate animals are also detectable. Dominant animals show higher expression 
of oestrogen receptor alpha, corticotropin releasing hormone (CRH) receptor 2, and 
androgen receptors in the nucleus accumbens and bed nucleus of the stria 
terminalis30, which regulate social behavior and behavioral responses to stress. 
Brain-derived neurotrophic factor (BDNF), which is related to neural cell functions, 
including adult neurogenesis, is expressed more highly in the hippocampus of 
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dominant mice than subordinate mice31. These animal studies suggest that agonistic 
interactions between male mice alter neurological function in individuals kept 
under social conditions. Therefore, hierarchy in the mouse affects behavior and 
gene expression, resulting in mood disorder such as depression, and it is differently 
regulated in dominant and subordinate mice.
2. Depression
2-1. Overview of depression
Major depressive disorder (MDD) is the most common psychiatric 
disorder and is a leading cause of suicide32. MDD affects more than 300 million 
people worldwide in all age groups and has a higher frequency among other 
psychiatric disorders33,34. It is one of the leading causes of disability, which can 
induce suffering, reduce productivity, and negatively influence on social 
relationships35,36. Approximately 800,000 people die by suicide every year due to 
the depressive disorders37,38, and it causes considerable damage to the economy 
such as the costs related to the treatment39. When associated with other pathologies 
such as cardiovascular, endocrine and pulmonary diseases, it increases mortality 
levels, besides the already high risk of suicide40,41. It is more prevalent in female, 
being two to three times more frequent in women than in men39.
Stress is one major cause of onset of depression42. In particular, 
environmental factors are strongly influenced on the cause of depression in 
childhood43. People who grew up with the experience of maltreatment, physical 
punishment, family disruption such as parental divorce in childhood, and stressful 
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life are more likely to have poor mental health and depression44. Furthermore, 
children from socio-economically disadvantaged families are more likely to suffer 
from substance dependence and depression when they become an adult44,45. The 
number of adverse experiences also had a graded relationship to alcoholism and 
depression in adulthood45.
A mouse study provided evidence of the existence of major differences in 
individual’s susceptibility to stress46-48. Dominant individuals were the ones 
showing a strong susceptibility profile as indicated by strong social avoidance 
following chronic social defeat stress (CSDS), while subordinate mice were not 
affected. Furthermore, in subordinates rather than dominants, levels of these 
metabolites were increased after exposure to CSDS47. This study provide an insight 
that will facilitate progress on the identification of the neurobiological mechanisms 
inherent to vulnerability to stress and those that foster resilience.
Various brain regions are involved in depressive symptom. In particular, 
impaired function in the prefrontal cortex (PFC) region contributes to 
depression49,50, and the therapeutic response produced by rapid-acting 
antidepressants such as ketamine are mediated by PFC activity51,52. Preclinical 
studies indicate that glutamatergic signaling in the dmPFC is critical to the 
therapeutic actions of ketamine53. A low dose of ketamine produces a paradoxical 
burst of glutamate in the mPFC, and neuronal silencing of the mPFC blocks the 
antidepressant actions of ketamine53. A key role for mPFC is also supported by 
optogenetic studies demonstrating that photostimulation of channelrhodopsin-2 
(ChR2) expressing mPFC pyramidal neurons is sufficient to reproduce the rapid 
and sustained antidepressant behavioral actions of ketamine52. The dmPFC serves 
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as a central hub that can shape the activity in a distributed network of output 
structures, including regulation of behavioral and autonomic responses to stress.
2-2. Glial cells and depression
Astrocytes are arguably the most abundant glial cells in the central 
nervous system (CNS)54. In brain, astrocytes are the most abundant and versatile 
cells participating in most of brain functions55,56. Mounting evidence supports the 
contention that numerical and morphological alterations of astrocytes in the
frontolimbic systems are closely associated with depression, as revealed in 
post‐mortem studies of patients with MDD or suicide completers57. 
Astrocyte‐specific markers such as glial fibrillary acidic protein (GFAP) and S100 
calcium-binding protein b (S100b) have consistently yielded significant reductions 
in the number and density of astrocytes in the PFC58,59. These reductions are 
paralleled by astrocyte hypotrophy, that is, shrinkage of the size of 
GFAP‐expressing cell bodies and processes in younger patients with MDD. In 
particular, the expression levels of the GFAP gene and protein are consistently 
decreased in the PFC58,60.
One of the most consistent findings in postmortem studies of MDD 
patients is a decrease in the density and number of astrocytes, as well as reduction 
in the size of neuronal cell bodies, in cortical regions of dmPFC58,61. The decreases 
in glial density are accompanied by a reduction of astrocytic markers, such as 
GFAP61. These observations indicate that glial alterations in the dmPFC contribute 
to depressive symptom58, which is a consequence or cause of the illness. A mouse 
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study provided the evidence of astrocyte loss in the dmPFC is sufficient to induce 
depressive-like behavior of rodent58. According to this study, L-a-aminoadipic acid 
(L-AAA) was infused into dmPFC. After L-AAA infusions, it induced decrease the 
density of astrocytes in the prelimbic cortex of dmPFC region, and provoked a 
reduction of dendritic length and complexity of the processes of GFAP-positive 
cells, suggesting astrocytic atrophy. L-AAA infusion into dmPFC region also 
induced anhedonia, anxiety, and depressive-like behavior in rats60. These behaviors 
were similar to those who received chronic unpredictable stress (CUS)62. 
Findings from clinical and preclinical studies suggest that astrocyte 
pathology may be a potential contributor to the pathophysiology and pathogenesis 
of major depression57,63. Many other astrocytic functions are altered in MDD, 
including ion and water homeostasis64, g-aminobutyric acid (GABA) and 
monoamine recycling65, blood brain barrier (BBB) integrity66, gliogenesis67, and 
synaptogenesis68. Most of these alterations target anti-depressants. These suggest 
that MDD is considered as a disease of astrocyte pathology, and highlight previous 
studies on promising strategies that direct target of astrocytes for the development 
of novel antidepressant treatments.
2-3. Therapeutic trials for depression
Antidepressants are a class of drugs that reduce symptoms of depressive 
disorders by correcting chemical imbalances of neurotransmitters in the brain69,70. 
Chemical imbalances may be responsible for changes in mood and behavior. 
Neurotransmitters are vital, as they are the communication link between neuronal
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cells in the brain. The prevalent neurotransmitters in the brain specific to 
depression are serotonin71,72, dopamine73,74, and norepinephrine75,76. In general, 
antidepressants work by inhibiting the reuptake of specific neurotransmitters, hence 
increasing their levels around the synapses within the brain, such as selective 
serotonin reuptake inhibitors (SSRIs), antidepressants that will affect serotonin 
levels in the brain.
Most antidepressants increase the extracellular serotonin or noradrenaline 
(NA) levels by inhibiting the reuptake of monoamine in presynaptic terminals. 
Although changes in extracellular monoamine levels occur soon after the drug 
administration, the clinical antidepressant effect develops slowly over several 
weeks of continuous treatment77. Clinical and animal studies have suggested that 
several neurotrophic/growth factors play important roles in the efficacy of anti-
depressant, which is assumed to be associated with neuronal plasticity, such as 
neurogenesis and synaptogenesis78-80. Clinical studies have indicated that lower 
levels of fibroblast growth factor-2 (FGF-2), BDNF, and glial cell line-derived 
neurotrophic factor (GDNF) in the postmortem brain or blood from patients with 
MDD were attenuated by antidepressant medications77,81. Animal studies have 
shown that FGF-2, BDNF, and vascular endothelial growth factor (VEGF) were 
induced by antidepressant treatment in several brain regions82, and the 
administration of FGF-2, BDNF, VEGF, and nerve growth factor (NGF) to rodents 
produced antidepressant-like effects81.
These neurotrophic/growth factors are produced not only in neurons, but 
also in astrocytes77,83. Astrocytes have monoaminergic receptors, and regulate the 
production of neurotrophic/growth factors including FGF-2, BDNF, GDNF and 
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NGF through the activation of monoaminergic receptors84. These findings suggest 
that astrocytes, as well as neurons, play important roles for the regulation of 
neurotrophic/growth factors by antidepressants in the brain. These reports suggest a 
novel concept that antidepressants directly act on astrocytes.
Although several effective treatment of anti-depressants, it is estimated 
that one-third of depressed patients do not respond adequately to conventional 
antidepressant drugs85,86. Moreover, not only the slow onset of their therapeutic 
effects also restricts antidepressant use 87,88 but also side effects exist when using 
the drugs89,90.
3. In vivo manipulation
Optogenetics is a novel biological technique based on a variety of light-
sensitive proteins called opsins, which include microbial ion channels and ion 
pumps as well as engineered G-protein coupled receptor (GPCR)91,92. Following 
absorption of a specific wavelength of light, an opsin undergoes a conformational 
change that triggers diverse cellular changes in opsin-expressing cells. Some of the 
opsins induce the translocation of ions, and others activate intracellular signaling 
cascades, such as G protein-mediated signaling. Since most of these opsins do not 
exist in experimental-model organisms, and photostimulation itself has a negligible 
effect on cells and tissues, optogenetics has instead been used as a powerful
experimental tool to manipulate specific populations of cells both in vitro and in 
vivo by means of a combinatorial approach of cell type-specific promoters and 
additional genetic tricks. This technique has also enabled the manipulation of 
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cellular activity with millisecond-scale temporal precision91. The timeresolved 
stimulation has made possible the revelation of causal relationships between 
manipulated cellular activity and functional outcomes, particularly in the study of 
neuronal circuits mediating specific behaviors. 
There are several opsins which can be utilized for the manipulation of 
neuron cells such as ChR2, halorhodopsin (eNpHR), and archaerhodopsin (ArchT). 
Among those opsins, channelrhodopsin, originally identified in green algae, is a 
cation channel that becomes permeable to positively charged ions such as proton 
and sodium when it is stimulated with blue light93-95. When it is expressed in 
neurons, 473 nm light elicits an influx of cations, which causes depolarization and 
the firing of action potentials in the stimulated cells91.
Chemogenetics is based on engineered proteins, such as GPCRs and 
ligand-gated ion channels, that are no longer responsive or only very weakly 
responsive to their endogenous ligands but strongly respond to synthetic chemical 
ligands that are otherwise biologically inert96-98. For example, hM3Dq, one of the 
designer receptors exclusively activated by designer drugs (DREADDs), is 
generated by multiple cycles of randomized mutagenesis of the human M3 
muscarinic receptor, which is linked to the Gq protein99. It is neither sensitive to 
the endogenous muscarinic acetylcholine receptor ligand acetylcholine nor is it 
constitutively active, but it is strongly activated in response to a synthetic ligand, 
clozapine-N-oxide (CNO), with nanomolar potency96. In response to CNO, hM3Dq 
can induce an enhancement of neuronal excitability that can lead to burst-like 




Social status is crucial for maintain individual’s life and mental health. 
Individuals with low social status are more vulnerable to psychiatric disorder such 
as depression. Recent study revealed that mouse social hierarchy is directly 
modulated by the layer V pyramidal neurons in dmPFC. Although increasing 
evidence indicate that neural activation is affected by nearby glial cells such as 
astrocyte, the role of astrocyte in the relation between dominance and depression is 
unknown. In this study, I tried to elucidate the involvement of dmPFC astrocyte in 
mouse dominance and depressive behaviors. To do this, I tried to series of 
experiments with the following specific aims:
1. To elucidate the role of dmPFC astrocyte in mouse social dominance 
behavior.
2. To find the effects of dmPFC astrocyte activation-induced dominancy 
on depression.
The research on the above specific aims is addressed in subsequent two chapters.
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Chapter I
The role of dmPFC astrocytes in mouse dominance behavior
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Abstract
Dominance behavior is an instinct behavior for survival in animal society. 
Recent study have indicated that neural activation in the dorsomedial prefrontal 
cortex (dmPFC) is implicated in the graduation and maintenance of dominance 
hierarchies. However, although increasing evidences show that astrocytes can 
directly affect neural activity, the role of astrocytes in dominance behavior has not 
been investigated. In this regard, I investigated the role of dmPFC astrocyte in 
mouse dominance behavior.
Both chemogenetic and optogenetic astrocyte activation enhanced 
excitatory synaptic inputs of layer V pyramidal neurons of the dmPFC by 
glutamate release without affecting neuronal excitability. Such dmPFC astrocyte 
activation in subordinate mice induced both a hierarchical rank increase by 
increasing the persistence of defensive behavior. As a mechanism, increased 
extracellular glutamate was observed after optogenetic dmPFC astrocyte 
stimulation. Also, surface AMPA receptor expression correlated miniature 
excitatory postsynaptic current (mEPSC) amplitude after rank elevation of rank-4 
mice. 
In this chapter, data show that social dominance can be manipulated by 
dmPFC astrocyte via glutamate release. The results suggest a novel behavioral 
strategy to change social rank. 
Key words: Social hierarchy, Dominance behavior, Astrocyte, Dorsomedial 
prefrontal cortex (dmPFC), Glutamate, AMPA receptor
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Introduction
Social hierarchy is a naturally occurring and evolutionarily conserved 
instinct phenomenon that serves as a guiding principle for the access to resources 
such as food, mating probabilities and resting spots102,103. Achieving and remaining 
at a high social status are essential for survival in both human and animal society. 
Moreover, it has profound influences on health and disease in both animals and 
humans104. There is a strong correlation between social status and psychiatric 
conditions; those with lower social status are more vulnerable to depression due to 
social defeat from others, while those with high social status have greater self-
esteem and psychological health3,23. Efforts to reach a higher social status and 
maintain it in animal society are represented by dominance behavior such as 
offensive action and resistance to opponents. Such dominance behaviors can be 
seen across various species13,105,106, making this an instinctive behavior 
evolutionally preserved across the animal kingdom.
The establishment of social dominance relies on the well-organization and 
orchestration of multiple brain regions such as dorsomedial prefrontal cortex 
(dmPFC), hippocampus, amygdala and nucleus accumbens107. Among them, recent 
studies show that the dmPFC is a key neural substrate controlling mouse 
dominance behavior13,14. Specifically, the strength of synaptic input to dmPFC 
layer V pyramidal neurons correlates with dominance behavior and social rank13. 
Also, ablation of BDNF/Tropomyosin receptor kinase B (TrkB) signals in the 
inhibitory neurons increases social dominance, which is reversed by optogenetic 
silencing of the excitatory neurons in the dmPFC108. Furthermore, repetitive 
１６
winning experiences of mice in tube tests potentiates synaptic activity of the 
mediodorsal thalamus (MDT) to the dmPFC circuit, which is necessary and 
sufficient for the maintenance of dominance hierarchy in mice14. Accordingly, how 
to potentiate the synaptic activity of dmPFC neurons is the key issue in maintaining 
dominance in social hierarchies and achieving the ‘winner effect’.
Pioneering studies indicate that astrocytes, a component of the tripartite 
synapse, play a critical role in regulating synaptic activity. Chemogenetic astrocyte 
activation induces de novo long-term potentiation (LTP) in the Schaffer collateral 
pathway of the hippocampus109. In addition, spinal cord astrocyte activation causes 
gliogenic LTP at synapses between C-fibers and lamina I neurons of the spinal 
cord110. Therefore, astrocytes can induce and maintain neuronal synaptic 
potentiation via various gliotransmitters111-113. In addition, increasing evidence 
supports that astrocytes can directly affect mouse behaviors by regulating synaptic 
transmission between pre- and post-synaptic neurons114,115. For instance, 
hippocampal astrocytes modulate mouse memory performance by affecting 
NMDA-dependent long-term potentiation109 and long-term depression116 in the 
hippocampal CA1 region. Likewise, astrocytes in the hypothalamic arcuate nucleus 
inhibit food uptake by inactivating agouti-related peptide neurons via adenosine A1 
receptors117. However, although astrocyte cell in brain can directly affect and 
change various mouse behaviors, it is still unknown whether mouse dominance 
behavior is affected by astrocyte. Specific regulatory mechanisms of such 
astrocyte-regulated mouse behaviors are different depending on the brain sub-
regions involved, however, regulation of synaptic transmission of each neural 
circuit responsible for the behaviors by astrocyte-derived gliotransmitters has been 
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suggested as a common denominating mechanism118,119. Therefore, given such a 
role for astrocytes, it is conceivable that astrocyte activity may influence the 
dominance hierarchy of mice by the effects on dmPFC synaptic activity. Here, I 
explored whether mouse dominance hierarchy could be manipulated by 




Six to 16-week-old male C57BL/6J mice of similar body weights were used for 
experiments. The animals were housed and maintained in a controlled environment 
at 22-24°C and 55% humidity with 12 h light/dark cycles and fed regular rodent 
chow and tap water ad libitum. All animal care was guided by the Seoul National 
University Institutional Animal Care and Use Committee (SNU IACUC, SNU-
180416-3).
Stereotaxic Viral delivery
Nine to 10-week-old wild type male mice that showed stable hierarchy in cages 
were used for viral delivery. Animals were anesthetized with isoflurane and secured 
in a stereotaxic frame (Stoelting Co., Wood Dale, IL, USA). Holes the size of the 
injection needle were drilled into the skull, and bilateral or unilateral injections 
with 0.7 ml (titer 1013 GC/ml) of adeno-associated virus with serotype DJ (AAVDJ) 
were administered in each side. The injection syringe (Hamilton Company, Reno, 
NV, USA) delivered the AAVDJ at a constant volume of 0.1 ml/min using a syringe 
pump (Stoelting Co.). The needle was left in place for 3 min after each injection to 
minimize the upward flow of the viral solution after raising the needle. The 
injection coordinates of the prelimbic (PL) cortex of the dmPFC were angle: 10°, 
AP: +2.43, ML: ±0.61, DV: -1.78 from bregma. Mono fiber-optic cannula were 
bilaterally implanted 1 week after the viral injection, 400 mm above the viral 
injection site (angle: 10°, AP: +2.43, ML: ±0.61, DV: -1.38 from bregma). Anchor 
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screws were located in the skull and fixed with Zinc Polycarboxylate dental cement. 
AAVDJ-GFAP-mCherry, AAVDJ-GFAP-ChR2-mCherry, AAVDJ-hSyn1-mCherry, 
and AAVDJ-hSyn1-ChR2-mCherry were purchased from the Korea Institute of 
Science and Technology (KIST, Seoul, Korea). Animals injected with virus were 
used for assessments of behaviors 3 weeks after the injection. Animals injected 
with AAVDJ but showing no detectable viral expression in the target region were 
excluded from the analyses.
Simultaneous stereotaxic implantation of optic fiber and guide cannula
To assess AMPA or NMDA-receptor mediated dominance behavior, both a guide 
cannula (Plastic1, Roanoke, VA, USA) and mono fiber-optic cannula were 
implanted in the same region simultaneously. With the identical stereotaxic 
procedure mentioned above, we implanted a guide cannula (C315GMN) covered 
by its dummy (C315CMN) (angle: -10°, AP: +2.43, ML: 0.01, DV: -1.58 from 
bregma) and a mono fiber-optic cannula (angle: +20°, AP: +2.43, ML: +0.94, DV: -
1.46 from bregma) to target the right dmPFC. The end of the guide cannula was 
200 mm above, and optic fiber was 400 mm above the target region. To perform in 
vivo microdialysis, we simultaneously implanted both a CMA7 guide cannula 
(CMA Microdialysis, CMAP000137, Kista, Sweden) (angle: -10°, AP: +2.43, ML: 
0.01, DV: -1.58 from bregma) and a mono fiber-optic cannula (angle: +20°, AP: 




On the day of all behavioral testing, animals were moved to the test room and left 
to habituate for at least 1 h. The light condition of the test room was maintained at 
the same intensity (100 lux) as the animal rooms under daylight conditions.
Tube test. The tube test was conducted as described 120. We used a transparent 
Plexiglas tube with 30 cm length and 3 cm inner diameter. Six-week-old male mice 
were housed in groups of 4 for at least 2 weeks before tube test. Before the main 
test, each mouse was trained to go through the tube for 10 trials in two consecutive 
days. On the test day, pairs of mice were released into the opposite ends and met at 
the middle of the tube. The tube test was performed for 2 min. If no winner or loser 
was decided within 2 min, the test was repeated. Between each trial, the tube was 
cleaned with 70% ethanol. Within each cage of four pairs, mice were randomly 
assigned such that each mouse would meet every other mouse of the group only 
once, resulting in six matches per cage. All 6 pairs of mice were tested daily with a 
round robin design and ranks were determined by total number of wins. Only cage 
mates that maintained stable ranks for at least 3 or 4 days were used for further 
experiments. The behaviors were videotaped and both push and resistance 
behaviors were counted. 
Tube test with optogenetic stimulation. We used optogenetic manipulation of 
dmPFC astrocytes and neurons in mice implanted with a mono fiber-optic cannula 
expressing ChR2 in astrocytes or neurons, respectively. We used 200 mm optic 
fibers (Thorlabs Inc., FP200URT, Neuton, NJ, USA) with a 1.25 mm ceramic 
ferrule (Thorlabs Inc., CFLC230-10) for bilateral stimulation and 300 mm optic 
fibers (Thorlabs Inc., FT300EMT) with 2.5 mm ceramic ferrules (Thorlabs Inc., 
CF340-10) for unilateral stimulation. We considered only cage mates with a stable 
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tube test rank for at least 3 or 4 consecutive days, and all four mice were implanted 
with an optic fiber in the dmPFC region. We used a tube opened with a 1.2 cm slit 
at the top of the tube. All four mice were habituated to the fiber connection and 
tested in the tube with fake optic fibers for 3 days before the main experiment. On 
test day, in the mice expressing AAVDJ-GFAP-ChR2-mCherry (GFAP-ChR2 mice), 
473 nm blue light delivery (20 Hz, 25 ms of pulse duration) (Shanghai Laser & 
Optic Century, Shanghai, China) was applied 20~30 seconds before mice entered 
the tube. In the mice expressing AAVDJ-hSyn1-ChR2-mCherry (hSyn1-ChR2 
mice), the blue light was applied right before entering the tube. Optogenetically 
stimulated rank-4 mice were matched with rank-3 mice first, and then with mice 
with a larger rank difference, namely rank-2 and rank-1 mice. If rank changed in 
the tube test, we switched the mouse pair to the opposite sides of the tube and 
repeated the test. We considered a rank change successful only when the rank-4 
mice won from both sides of the tube. We applied light intensity of around 1 ~ 10 
mW.
Dominance competition between the mice expressing neuronal ChR2 and 
astrocytic ChR2. We first measured the winning rate of each test mouse (GFAP-
ChR2 and hSyn1-ChR2 mice) competing with their matched control (expressing 
AAVDJ-GFAP-mCherry or AAVDJ-hSyn1-mCherry). All control and test mice 
were individually housed for at least two weeks to avoid dominancy among the 
cage mates. On the test day, after 2 days of tube training, each test mouse was 
matched against 10 control mice, and the winning rates of all test mice were 
averaged. We next compared dominance competition between the mice with 
neuronal and astrocytic ChR2 activation (473 nm, 20 Hz, 25 ms of pulse duration). 
２２
The mice from each group were randomly paired with the mice from the other 
group, and the winner was determined when one mouse won twice out of three 
tests (best of three). Different mice sets were used for the two experiments.
Tube test with optogenetic astrocyte stimulation delivering NBQX and vehicle.
We delivered NBQX (10 mM) via guide cannulas (C315GMN, Plastic1) 30 min 
prior to the tube test 121. In the tube test, light stimulation (473 nm, 20 Hz, 25 ms of 
pulse duration) was provided only to rank-4 mice. Optic stimulation was provided 
only 0.5 h after drug delivery and the behavior test was performed at various time 
points (0.5, 1.5, 3, and 24 h after drug delivery).
Resident-intruder test. A resident-intruder test was applied by modifying the 
method to detect reliable aggressiveness of C57BL/6J male mice122.  Male and 
female mice were co-housed together for at least 3-4 weeks before the main test.
On the test day, the female mouse was removed from the cage and a new, 1-week 
younger C57BL/6J male mouse was introduced as an intruder for 10 min. The 
behaviors of the residents with or without light stimulation (473 nm, 20 Hz, 25 ms 
of pulse duration) were videotaped for analysis. Aggressive behaviors such as 
chasing duration, attack frequency, and attack duration were counted.
Open field test (OFT). The apparatus consisted of a brightly illuminated 40 cm x
40 cm square arena surrounded by a 40 cm high wall. Mice were individually 
placed in the center of the arena, and their locomotion activity was monitored by an 
automatic system for 10 min. Light stimulation of 473 nm was intermittently 
turned on and off on the test mice (GFAP-ChR2 mice and GFAP-mCherry mice) 
with 1 min intervals. Total distance and time spent in the center zone per minute 
were analyzed by automated video tracking system (SMART, Panlab SL, 
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Barcelona, Spain). The activity chamber was cleaned with 70% ethanol after each 
use to eliminate any olfactory cues from the previously tested mouse.
Elevated plus maze (EPM). The behavioral apparatus consisted of two open arms 
(width 5 cm x length 30 cm) and two closed arms (width 5 cm x length 30 cm) 
elevated 60 cm above the floor and dimly illuminated. Mice were placed 
individually in the center of the maze facing an open arm and allowed to freely 
explore for 5 min. Light was delivered during the whole experimental session to 
GFAP-ChR2 mice and their control group. The time spent in each arm was 
analyzed using a video tracking system. The maze was cleaned with 70% ethanol 
after each test to prevent influence from the previously tested mouse.
Forced swim test (FST). We conducted forced swim tests by placing each animal 
individually in transparent cylinders filled with water (23-25°C; depth 15 cm) for 5 
min. Immobility in the FST was defined as the state in which mice were judged to 
be making only the movements necessary to keep their head above the surface. 
Light was delivered during the whole experimental session to GFAP-ChR2 mice 
and their control group. Both trials were videotaped and immobility time was 
analyzed using a video tracking system.
Experimental protocols including OFT, EPM, and FST were designed to take into 
account potential stress that could affect test mice behavior123. After the tube test, 
behavioral assessment was performed in the following sequential order to minimize 
stress effects: OFT, EPM, and FST. We performed each behavior test at least 48 h 
after the previous test to minimize potential stress effects.
OFT, EPM, and FST with treatment of NBQX or vehicle. We stereotactically 
implanted both an optic fiber and guide cannula simultaneously into the dmPFC 
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region. Three days after the surgery, we performed behavior tests 30 min after drug 
delivery via guide cannula. NBQX (10 mM) were delivered at a volume of 1 ml at a 
rate of 0.5 ml/min. Each behavior was tested at least 48 h after the previous test to 
minimize potential stress effects.
Primary astrocyte culture and in vitro Ca2+ assay
Primary astrocytes were isolated from the hippocampus and cortex of postnatal day 
1 mice and prepared using a modified established protocol124. Briefly, after 
removing the meninges from the cerebral hemisphere, the tissue was dissociated 
into a single-cell suspension by gentle repetitive pipetting and filtered through a 70 
μm filter. The cells were cultured in DMEM supplemented with 10 mM HEPES, 
10% FBS, 2 mM L-glutamine, and 1X antibiotic/antimycotic in 75 cm2 flasks at 
37°C in a 5% CO2 incubator. The medium was changed every 5 days. After 2 
weeks, the flask was shaken at 250 rpm for 2 h at 37°C, treated with 100 mM L-
leucine methyl ester for 60 min to remove the microglial cells, and harvested using 
trypsinization (0.25% trypsin, 0.02% EDTA). Calcium response in astrocytes 
expressed ChR2 was measured by single-cell calcium imaging using Rhod-2AM 
(Invitrogen, Carlsbad, CA, USA). Primary cells were plated on PDL-coated cover 
glasses and incubated overnight. Cells were incubated for 50 min at 37°C with 2 
μM Rhod-2AM in HBSS containing 25 mM HEPES (pH 7.5) and washed with 
HBSS-HEPES twice before assays. A baseline reading was taken for 100 sec 
before blue light (473 nm, 20 Hz, 25 ms) stimulation. Intracellular calcium levels 
were measured by digital video microfluorometry with an intensified charge-
coupled device camera (CasCade, Roper Scientific, Trenton, NJ, USA) coupled to 
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a microscope and analyzed with MetaFluor software (Universal Imaging Corp., 
Downington, PA, USA). Increases in the fluorescence intensity over baseline were 
calculated for each trace and are reported as ΔF/F0.
Immunohistochemistry
The whole brain was saline-perfused, fixed in 4% paraformaldehyde in 0.1 M PBS 
overnight at 4°C, and dehydrated with 30% sucrose for 3 days. Coronal sections 
with a thickness of 50 μm were incubated in cryopreservation solution at -20°C 
until immunohistochemical staining was performed. The sections were blocked in a 
blocking solution containing 5% normal donkey serum (Jackson Immunoresearch, 
Bar Harbor, ME, USA), 2% BSA (Sigma), and 0.1% Triton X-100 (Sigma) for 1 h 
at room temperature. The sections were then incubated with mouse anti-NeuN 
(1:1,000, Millipore, MAB377B), mouse GFAP (1:1,000, Millipore, MAB360), 
rabbit Iba1 (1:1,000, Wako, 019-19741), and rabbit c-Fos (1:1,000, Oncogene, 
PC05-100UG) antibodies overnight at 4°C in blocking solution. After washing with 
0.1 M PBS containing 0.1% Triton X-100, the sections were incubated for 2 h with 
FITC-conjugated secondary antibodies (1:200, Jackson Immunoresearch, 715-095-
151, 711-095-152) in blocking solution at room temperature, washed 3 times, and 
then mounted on gelatin-coated slide glass using Vectashield (Vector Laboratories, 
Inc. Burlingame, CA, USA). Fluorescent images of the mounted sections were 
obtained with a confocal microscope (LSM800, Carl Zeiss, Jena, Germany).
Electrophysiology
Transverse prefrontal cortical slices (300 mm) were prepared. Briefly, mice were 
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anesthetized with isoflurane and decapitated, and the brains were rapidly removed 
and placed in ice-cold, oxygenated (95% O2 and 5% CO2), low-Ca
2+/high-Mg2+
dissection buffer containing 5 mM KCl, 1.23 mM NaH2PO4, 26 mM NaHCO3, 10 
mM dextrose, 0.5 mM CaCl2, 10 mM MgCl2, and 212.7 mM sucrose. Slices were 
transferred to a holding chamber in an incubator containing oxygenated (95% O2
and 5% CO2) artificial cerebrospinal fluid (ACSF) composed of 124 mM NaCl, 5 
mM KCl, 1.23 mM NaH2PO4, 26 mM NaHCO3, 10 mM dextrose, 2.5 mM CaCl2, 
and 1.5 mM MgCl2 at 28-30°C for at least 1 h before recording. After recovery, 
slices were transferred to a recording chamber where they were perfused 
continuously with ACSF gassed with 95% O2/5% CO2 at a flow rate of 2 ml/min. 
Slices were equilibrated for 5 min prior to recordings, and all experiments were 
performed at 23-25°C. Recordings were obtained using a Multiclamp 700B 
amplifier (Molecular Devices, Sunnyvale, CA, USA) under visual control with 
differential interference contrast illumination on an upright microscope (BX51WI; 
Olympus, Tokyo, Japan). Patch pipettes (5–7 MΩ) were filled with 135 mM K-
gluconate, 8 mM NaCl, 10 mM HEPES, 2 mM ATP-Na, and 0.2 mM GTP-Na to 
record sEPSCs and mEPSCs in the voltage-clamp (VC) mode or neuronal 
excitability in the current-clamp (CC) mode (pH 7.4 and 280-290 mOsm). Only 
cells with access resistance < 20 MΩ and input resistance >100 MΩ were studied. 
The extracellular recording solution consisted of ACSF supplemented with 
picrotoxin (100 mM) and tetrodotoxin (1 mM) for mEPSC experiment. Data were 
acquired and analyzed using pClamp 10.5 (Molecular Devices). Signals were 
filtered at 2 kHz and digitized at 10 kHz using Digidata 1550A (Axon Instruments, 
Union City, CA, USA). 
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Gliotransmitter assays
A concentration of glutamate, D-serine, and ATP were measured using ELISA kits 
according to the respective manufacturer’s instructions (Glutamate Colorimetric 
Assay kit, Biovision, #K629-100; DL-serine Assay Kit, Biovision, #K743-100; 
ATP Assay System Bioluminescence Detection Kit, Sigma, #11 699 709 001). 
dmPFC tissue was collected from rank-1, rank-4, light stimulated rank-4-GFAP-
mCherry and rank-4-GFAP-ChR2 mice, respectively. All tissues were 
homogenized and centrifuged for the assay. All assays were conducted using a 96-
well microplate immediately after sample collection.
In vivo microdialysis with light stimulation
After surgery, a CMA7 microdialysis probe (shaft length 5 mm; shaft outer-
diameter 0.58 mm) was implanted through the guide cannula. The probe was 
connected to a CMA100 microinjection pump (CMA Microdialysis) with 
polyethylene tubing (PE 50) and FEP tubing (INSTECH, Plymouth meeting, PA, 
USA). Then the probe was perfused with ACSF (in mM: 149 NaCl, 2.8 KCl, 1.2 
MgCl2, 1.2 CaCl2, and 5.4 glucose, pH7.4) into the inlet of the probe at a flow rate 
of 1.5 μl/min. Perfusates from the outlet of the tubing were automatically collected 
in plastic vials at 8°C using a CMA 470 refrigerated fraction collector. Dialysates 
were collected over 30 min intervals for 3 h and used for measurement of 
glutamate from the second samples. Light was delivered for 5 min (473 nm, 20 Hz, 
25 ms of pulse duration, 1 min inter-stimulus interval) at 1.5 h after the beginning 
of the experiment. Dialysates were stored at -80°C and then glutamate 
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concentration was analyzed.
Surface protein biotinylation and immunoblot analysis
dmPFC tissues were prepared from 8- to 12-week-old rank-1, rank-4, rank-4-
GFAP-mCherry, and rank-4-GFAP-ChR2-mCherry mice using the same method of 
slice preparation as for electrophysiology and were sliced into 300 μm thickness. 
The mPFC slices were recovered for 30 min at 31°C in oxygenated ACSF. To 
biotinylate the surface proteins, the slices were incubated with 1mg/ml sulfo-NHS-
SS-biotin (Thermo Scientific, 21328) in ACSF at 4°C for 45 min. The slices were 
quenched with 100 mM glycine in ACSF at 4°C for 25 min after washing with 
ACSF. The quenched slices were lysed with RIPA buffer (50 mM Tris, pH7.5, 
0.1% SDS, 1% Triton X-100, 150 mM NaCl, 0.5 sodium deoxycholate and 2 mM 
EDTA) containing protease inhibitor cocktail (Sigma-Aldrich, 11836153001), and 
incubated at 4°C rotating for 30 min. The lysates were centrifuged at 15,000 g for 
15 min at 4oC and supernatant was collected. The concentration of protein was 
determined via BCA Protein Assay Kit (Thermo Scientific, 23225). To isolate 
biotinylated proteins, 200 μg of each sample was added to streptavidin-agarose 
beads (Thermo Scientific, 29200) and incubated at 4°C rotating overnight. The 
streptavidin-agarose beads were eluted with 2x laemmil sample buffer after 
washing with the lysis buffer and used for membrane surface proteins. Twenty μg 
of slice lysate was used for total proteins. The proteins were separated on SDS-
PAGE gels and then transferred onto PVDF membranes. The membranes were 
blocked in 5% skim milk in TBS-T for 1 h at room temperature and incubated with 
primary antibodies in blocking buffer at 4°C overnight. Primary antibodies to 
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GluA1 (1:1,000, Millipore, MAB2263) and GluA2 (1:1,000, Millipore, MAB397) 
were applied. After washing, membranes were incubated with horseradish 
peroxidase (HRP)-conjugated secondary antibodies for 1 h at room temperature. 
HRP was detected using Super Signal West Femto Maximum Sensitivity Substrate 
(Thermo Scientific, 34096) and a Bio-Image Analyzer (MicroChemi/DNR, Neve 
Yamin, Israel).
Statistics
Statistical significance was determined using the two-tailed Student’s t-test, paired 
t-test, Wilcoxon signed-rank test, or two-tailed Mann-Whitney U-test for 
comparison between two groups. For multiple comparisons, one-way ANOVA and 
Bonferroni’s multiple comparison tests were used. All data are represented as the 
mean ± s.e.m., and differences were considered statistically significant when the p-
value was less than 0.05.
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Results
Optogenetic activation of dmPFC astrocytes induces winning by enhancing 
resistance behavior in the tube test
I assessed mice social hierarchy through the tube test, which is stable and 
correlates well with other dominance measures120. Four 6-week-old male mice 
were housed per cage for at least 2 weeks prior to the tube test. Mice were tested 
pair-wise, and social rank was assessed on the basis of the number of wins against 
the other three cage mates. Cages in which the mice maintained a stable hierarchy 
for at least 3 consecutive days were considered as social hierarchy-established 
cages and utilized for further investigations (Fig. 1a). In tube tests among the cage 
mates, winner mice pushed and resisted more against loser mice (Fig. 1b). The 
body weight of the test mice did not vary depending on their social hierarchy from 
6 weeks to 13 weeks. However, after 14 weeks, body weight was divided into two 
groups (dominants vs. subordinates) (Fig. 1c and d). The percentage of hierarchy-
established cages was consistent (62~68%) regardless of tube test time of day (Fig. 
1e) or age of the mice tested (Fig. 1f), validating test consistency. 
dmPFC astrocyte activation while MDT-dmPFC neural circuit activation 
further potentiates and maintains rank elevation of rank-4 mice.
To investigate astrocyte function in behaving mice in vivo, I employed 
both chemogenetic and optogenetic techniques that enabled astrocyte activity 
manipulation. I simultaneously delivered AAVDJ-CamKII-ChR2-eGFP into right 
MDT and AAV5-gfaABC1D-hM3Dq-mCherry into right PL region of rank 4 mice 
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(Fig. 2a-c). After 2 weeks, I chemogenetically activated dmPFC astrocytes by 
introducing CNO (i.p., 3 mg/kg) while optogenetically activating MDT to dmPFC 
neural circuit. As previously reported14, optogenetic MDT-dmPFC circuit 
stimulation elevated social hierarchy of rank 4 mice (Fig. 2d gray). When we 
activated dmPFC astrocytes along with optogenetic MDT-dmPFC circuit 
stimulation, it further potentiated and maintained the elevated ranks of rank 4 mice 
(Fig. 2d yellow). 
Chemogenetic dmPFC astrocyte stimulation induces rank elevation of rank-4 
mice.
Considering that simultaneous activation of neuron and astrocyte can 
maintain hierarchical rank elevation, I next tested whether astrocyte alone can 
trigger rank change in rank-4 mice. To confirm if astrocyte activation per sei 
controls social rank, we infected AAV5-gfaABC1D-hM3Dq-mCherry into PL 
region and performed tube test with CNO injection (i.p., 3 mg/kg) (Fig. 3a). CNO-
injected rank 4 mice showed significant rank elevation at 2 and 6 h after CNO 
injection (Fig. 3b). Interestingly, chemogenetic astrocyte activation increased 
mouse resistance behavior but not pushing behavior during fight (Fig. 3c). To 
examine the effect of chemogenetic dmPFC astrocyte stimulation on synaptic input 
into dmPFC, I performed miniature excitatory post-synaptic current (mEPSC) of 
PL layer V pyramidal neurons using acute brain slices. The result showed 
significant increases in mEPSC frequency, but not mEPSC amplictude, in PL Layer 
V pyramidal neurons upon chemogenetic astrocyte stimulation (Fig. 3d).
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Optogenetic dmPFC astrocyte stimulation increases extracellular Ca2+.
Next, I employed optogenetic techniques that enabled astrocyte activity 
manipulation with temporal precision to investigate astrocyte function in behaving 
mice in vivo. Optogenetic activation of ChR2-expressing astrocytes has been 
shown to trigger an intracellular calcium increase in prior study125, as was 
confirmed in my study in vitro (Fig. 4a-c). Next, AAVDJ expressing ChR2 under 
the control of the astrocytic glial fibrillary acidic protein (GFAP) promotor 
(AAVDJ-GFAP-ChR2-mCherry) or control virus (AAVDJ-GFAP-mCherry) was 
injected into the right PL subregion of the dmPFC (Fig. 4d). Within the virally 
transduced region, ChR2 expression was limited to astrocytes with high specificity 
(> 97% of GFAP positive cells) (Fig. 4e). Co-staining with neuronal nuclei (NeuN)
and microglial marker Iba1 showed negligible overlaps (0.8% and 1.6%, 
respectively) (Fig. 4e). 
Optogenetic dmPFC astrocyte stimulation induces rank graduation of rank-4 
mice by increasing their resistance behavior.
Upon implanting an optic fiber 3 weeks after the viral injection, I 
delivered a 473-nm laser stimulation at 20-Hz (25 ms of pulse duration), a protocol 
that has been used to stimulate astrocytes125, to rank-4 mice 30 seconds prior to the 
tube test, and kept the light on throughout the test until the tube test was over 
maximum for two minutes. Upon light stimulation, the rank of AAVDJ-GFAP-
ChR2-mCherry-injected mice (GFAP-ChR2 mice), but not AAVDJ-GFAP-
mCherry-injected mice (GFAP-mCherry mice), was elevated significantly (Fig. 5a 
and b). Interestingly, optogenetic astrocyte stimulation increased resistance 
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behavior rather than pushing behavior during the fight (Fig. 5c and d), which was 
sufficient for rank graduation. There were no correlations between virus 
transduction area and rank change rate or time (Fig. 5e). Moreover, optogenetic 
astrocyte stimulation induced a rank change in around 80% of mice regardless of 
experimental conditions (light, dark or random phase) (Fig. 5f). In conclusion, 
dmPFC astrocyte activation induces dominance behavior by enhancing resistance 
against opponents during fights in the tube test.
Optogenetic astrocyte stimulation influences excitatory synaptic input to 
pyramidal neurons, but not their excitability
I next investigated the effect of astrocyte activation on the neuronal 
activity of layer V pyramidal neurons in the dmPFC. To examine the effect of 
optogenetic dmPFC astrocyte stimulation on synaptic release including miniature 
excitatory post-synaptic current (mEPSC) and spontaneous EPSC (sEPSC), I 
performed whole-cell recordings of dmPFC pyramidal neurons in this region in 
acute brain slice. In GFAP-ChR2 mice, the frequency of both mEPSCs and sEPSCs 
was significantly elevated not only during light stimulation but also when the light 
was turned off up to 2 min (Fig. 6a-c). Meanwhile, the amplitudes of mEPSCs and 
sEPSCs were not altered (Fig. 6c and d), and neither neuronal excitability nor the 
action potential threshold was affected by astrocyte activation (Fig. 7). These 
observations show that dmPFC astrocytic activation induced prolonged increases in 
the frequency of synaptic inputs, without altering the amplitude of synaptic 
currents and excitability.
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Optogenetic dmPFC astrocyte stimulation does not alter basal aggressive 
behavior.
I further investigated that whether dmPFC astrocyte stimulation affects 
basal aggressive behavior of mice. I performed resident-intruder (RI) test to 
investigate mouse aggressive behavior (Fig. 8a). Male C57BL/6J mice divided by 
two groups showing non-aggressive or aggressive behaviors (Fig. 8b). Then I 
optogenetically stimulated dmPFC astrocyte of resident mice whether they alter 
aggressiveness. Optogenetic dmPFC astrocyte stimulation did not affect basal 
aggressiveness in both non-aggressive (Fig. 8c) and aggressive mice (Fig. 8d). In 
conclusion, dmPFC astrocyte activation does not alter aggressiveness of mice.
Optogenetic dmPFC astrocyte stimulation does not alter locomotion, anxiety,
and depressive behaviors.
I also investigated that whether dmPFC astrocyte stimulation affects 
mouse locomotion and mood behaviors such as anxiety and depression. I 
performed OFT to investigate locomotive behavior, and EPM and FST to 
investigate mouse anxiety and depressive behaviors along with optogenetic dmPFC 
astrocyte stimulation. Optogenetic dmPFC astrocyte stimulation did not affect 
basal locomotion such as total distance traveled (Fig. 9a and b). Distance in center 
in OFT (Fig. 9c-e) and time in open arm in EPM (Fig. 9f and g) suggest that 
anxiety-like behavior did not altered by optogenetic dmPFC astrocyte stimulation. 
Furthermore, according to the result of time immobility in FST indicate that 
depressive-like behaviors did not altered by dmPFC astrocyte activation (Fig. 9h). 
In conclusion, dmPFC astrocyte activation does not alter mood behaviors such as 
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anxiety and depression of mice. In conclusion, dmPFC astrocyte activation was 
sufficient to induce dominance behavior by enhancing resistance against opponents
during fights in the tube test without affecting aggressiveness or mood.
Optogenetic dmPFC astrocyte stimulation induces extracellular glutamate 
release.
Next, I investigated putative gliotransmitters released from the astrocytes 
after light stimulation. Thus far three types of gliotransmitters have been reported 
as derived from activated astrocytes; D-serine, ATP, and glutamate126. In dmPFC 
tissue, only glutamate, and not D-serine, DL-serine, or ATP, was increased after 
optogenetic astrocyte stimulation (Fig. 10a). I also verified an increase in 
extracellular glutamate level in the dmPFC after astrocyte stimulation in vivo using 
microdialysis; dmPFC extracellular glutamate level increased right after 
optogenetic astrocyte stimulation in vivo (20-Hz, 25 ms, 5 min with 1 min interval), 
which lasted up to 1 h (Fig. 10b). 
Surface AMPA receptor expression is increased after optogenetc dmPFC 
astrocyte stimulation.
I expected the glutamate receptor-mediated synaptic current to be 
influenced by astrocyte-derived glutamate, and therefore conducted whole-cell 
patch clamp experiments to measure AMPA receptor-mediated synaptic current, as 
well as mEPSCs in the dmPFC slices of rank-1, rank-4, and light-stimulated rank-4 
mice. I found significantly lower mEPSC amplitudes in basal rank-4 mice 
compared to rank-1 mice (Fig. 11a). Of note, rank-4 mice who had raised their rank 
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upon optogenetic astrocyte stimulation exhibited elevated mEPSC amplitudes 
comparable to rank-1 mice without astrocyte stimulation (Fig. 11a). These results 
suggest that increased extracellular glutamate level by astrocyte stimulation 
elevated AMPA receptor-mediated synaptic input into dmPFC pyramidal neurons 
in rank-4 mice.
To investigate the molecular mechanisms underlying the correlation 
between dominance behavior and the amplitude of mEPSC current in dmPFC 
neurons, I measured membrane expression levels of GluA1 and GluA2, two major 
subunits of the AMPA receptor, in the dmPFC. Membrane GluA1 expression level 
in rank-4 mice was lower than in rank-1 mice, and was significantly increased by 
astrocyte stimulation (Fig. 11b). This change indicated that membrane GluA1 
levels correlate with social hierarchy. Meanwhile, membrane GluA2 expression 
level did not correlate with mice social hierarchy (Fig. 11b). 
AMPA receptor antagonist, NBQX, successfully block dmPFC astrocyte 
induced rank graduation.
I next tested if AMPA receptor function directly influenced dominance 
behavior. I implanted both a guide cannula and optic fiber in the PL subregion of 
the dmPFC to simultaneously block the AMPA receptor and stimulate astrocytes. I 
injected NBQX, an AMPA receptor antagonist, or vehicle to the PL area of rank-4 
mice in their home cage 30 min prior to the tube test (Fig. 12a). NBQX infusion 
almost completely abrogated the rank changes due to astrocyte stimulation (Fig. 
12b). NBQX treatment did not affect motor activity or mood, which were measured 
by the open field test, elevated plus maze, and force swim test (Fig. 13). Taken 
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together, these data support that glutamate released from astrocytes regulates 
AMPA receptor-mediated synaptic inputs to pyramidal neurons in the dmPFC and 
thereby modulates dominance competition.
Astrocyte stimulation induces dominancy as effectively as pyramidal neuron 
stimulation but with distinct behavioral strategy
Since dmPFC pyramidal neurons regulate dominance behavior as well13,14, I next 
compared astrocyte stimulation-induced dominance behavior with the results of 
pyramidal neuron stimulation. Mice were divided into two groups: one with 
neuronal ChR2 expression by AAVDJ-hSyn1-ChR2-mCherry injection (hSyn1-
ChR2 mice) and another with astrocytic ChR2 expression by AAVDJ-GFAP-ChR2-
mCherry injection (GFAP-ChR2 mice) in the dmPFC area. Upon light stimulation 
during the tube test (473 nm, 20 Hz, 25 ms), the average rank change of rank-4 
mice was comparable between these two groups (Fig. 14a and b). As previously 
reported, neuronal stimulation induced rank change by increasing both pushing and 
resisting behaviors (Fig. 14a)14. However, GFAP-ChR2 mice did not exhibit 
elevated pushing behavior, although the level of rank induction was similar to those 
of hSyn1-ChR2 mice (Fig. 14a). Next, I measured the winning rate of each group 
competing with their matched control (AAV-hSyn1-mCherry-injected mice and 
AAVDJ-GFAP-mCherry-injected mice, respectively) (Fig. 14b). Both groups 
showed comparable winning rates in the tube test against control mice (~75%) (Fig. 
14b). I then arranged matches between hSyn1-ChR2 mice and GFAP-ChR2 mice 
with light stimulation (473-nm, 20-Hz, 25 ms) (Fig. 14c). Since neuronal ChR2 
stimulation increased pushing behavior while astrocyte stimulation did not, I 
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expected hSyn1-ChR2 mice to dominate over GFAP-ChR2 mice. However, the 
winning rate between the two groups was not different; the winning rate of 
neuronal ChR2-stimulated mice was 53.8% and that of astrocyte ChR2-stimulated 
mice was 46.2% (Fig. 14c). These data indicate that an increase in resistance via
astrocyte stimulation contributed to mouse dominancy as much as an increase in 
pushing behavior via neuronal stimulation. Taken together, both neurons and 
astrocytes in the dmPFC equally contribute to mouse dominance behavior, however, 
their activation employs distinct behavioral strategy to achieve dominancy during 
social competition (Fig. 15).
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Figure 1. Formation of social hierarchy in the group-housed mice. a, Basal 
hierarchy by performing daily tube test of a mouse cage. b, The number of pushing 
and resistance behaviors per tube test trial of winner mice compared to losers 
(n=22 in each group). Two tailed t-test. c, Body weights of all cage mates (from 
rank-1 to rank-4 mice) measured every week from 6- to 16-week-old (n=17 in each 
group). The body weight of the test mice did not vary depending on their social 
hierarchy from 6 weeks to 13 weeks. However, after 14 weeks, body weight was 
divided into two groups (dominants vs. subordinates). d, Body weights of all cage 
mates at ages 8-, 12-, and 16-week-old. One-way ANOVA, Bonferroni post-hoc 
analysis. e and f, The percentage of hierarchy formation according to tube test 
schedules (experiments conducted in light, dark, and random phases), and mouse 
ages. The percentage of hierarchy-established cages was consistent regardless of 
tube test time of day (62~68%) or age of the mice tested (61~68%) validating test 
consistency. *p < 0.05; ***p < 0.001; NS, not significant. Data are presented as the 
mean ± s.e.m.
４０
Figure 2. Simultaneous activation of MDT-dmPFC neural circuit and dmPFC 
astrocytes elevates and maintains rank graduation. a, Schematic illustration of 
virus injection of AAV5-gfaABC1D-hM3Dq-mCherry into dmPFC and AAVDJ-
CamKII-ChR2-eGFP into MDT region, and simultaneous activation of dmPFC 
astrocytes and MDT-dmPFC neural circuit. b, Virus expression in the MDT and 
dmPFC region. Scale bar, (Left) 500 mm and (Middle) 1 mm. c, Astrocytes 
(hM3Dq-mCherry) in the PL subregion of dmPFC. eGFP fluorescence in the 
synaptic terminal of MDT neurons can be detected in this region. Scale bar, 100 
mm. d, Optogenetic MDT-dmPFC circuit stimulation elevates hierarchical rank of 
rank-4 mice (gray). Chemogenetic activation of dmPFC astrocytes (i.p. injection of 
CNO (3 mg/kg)) along with optogenetic MDT-dmPFC circuit stimulation 
potentiated and maintained the elevated ranks of rank-4 mice (red). *p < 0.05; NS, 
not significant. Data are presented as the mean ± s.e.m.
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Figure 3. Chemogenetic activation of astrocyte in dmPFC increases 
hierarchical rank elevation of rank-4 mice by enhancing resistance behavior, 
and increases excitatory synaptic input into layer V pyramidal neuron. a, 
Expression of AAV5-gfaABC1D-hM3Dq-mCherry in the prelimbic cortex of 
dmPFC. Scale bar, 1 mm. b, Mean rank change of chemogenetic astrocyte-
stimulated rank-4 mice injected with AAV5-gfaABC1D-hM3Dq-mCherry virus 
compared to their control group (AAVDJ-GFAP-mCherry) (n=5 in each group). 
Wilcoxon signed-rank test. c, Comparison of behavioral performances such as 
pushing and resistance of rank-1 and rank-4 mice during the tube competition (n=5 
in each group). One-way ANOVA, Bonferroni post-hoc analysis. d, (Left) 
Representative traces of mEPSC events, and (Middle and Right) amplitude and 
frequency of mEPSC (10 cells from 3 GFAP-mCherry mice and 13 cells from 3 
gfaABC1D-hM3Dq mice). Paired t-test. *p < 0.05; ***p < 0.001; NS, not 
significant. Data are presented as the mean ± s.e.m.
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Figure 4. Optogenetic astrocyte stimulation increases intracellular Ca2+
response in vitro, and astrocyte-specific expression of ChR2 in dmPFC region 
in vivo. a, Fluorescence images of ChR2 (EYFP), astrocytes (GFAP), and both 
merged in cultured primary astrocytes. Scale bar, 100 mm. b, Ca2+ response in 
primary astrocytes in vitro. Rhod-2 fluorescence from individual astrocytes (gray) 
and averaged trace (red) in ChR2-positive astrocytes (7 cells). Optogenetic 
stimulation of ChR2-expressing astrocytes triggered an intracellular calcium 
increase. Scale bar, 1 min. c, Ca2+ responses of ‘pre’ and ‘post’ light stimulation of 
astrocytes. (Both ‘pre’ and ‘post’ are corresponded to the arrows in b). Two-tailed 
Mann-Whitney U-test. d, AAVDJ-GFAP-ChR2-mCherry was injected into the PL 
subregion of the dmPFC. Scale bar, 1 mm. e, mCherry signals (ChR2-positive 
cells) are expressed in astrocytes with more than 97% specificity. Negligible co-
localization of ChR2 (mCherry) with the neuronal nuclear marker NeuN (0.8%) or 
the microglia marker Iba1 (1.6%) was detected. Scale bar, 100 mm. ***p<0.001. 
Data are presented as the mean ± s.e.m.
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Figure 5. Optogenetic activation of dmPFC astrocytes induces winning by 
enhancing resistance behavior. a, GFAP-ChR2 virus expression in the dmPFC 
region. b, Individual rank change of dmPFC astrocyte-stimulated rank-4 mice 
injected with (Left) AAVDJ-GFAP-ChR2-mCherry (n=8) and (Right) AAVDJ-
GFAP-mCherry (n=5) (20-Hz). c, Mean rank change of astrocyte-stimulated rank-4 
mice injected with AAVDJ-GFAP-ChR2-mCherry virus compared to their control 
group (GFAP-mCherry) (n=5 for GFAP-mCherry and n=8 for GFAP-ChR2). 
Wilcoxon signed-rank test. d, Comparison of behavioral performances such as 
pushing and resistance of rank-1 and rank-4 mice during the tube competition 
(n=13 for rank-1 and rank-4 mice, and n=17 for AAVDJ-GFAP-ChR2-injected 
rank-4 mice with light stimulation (blue bars)). One-way ANOVA, Bonferroni 
post-hoc analysis e, Correlation between the virus infected area in the PL subregion 
of the dmPFC and rank changes. Pearson’s correlation. f, The probability of rank 
change of rank-4 mice via optogenetic dmPFC astrocyte stimulation (tube tests 
were conducted in light, dark, and random phases). Optogenetic astrocyte 
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stimulation induced a rank change in around 80% of mice regardless of 
experimental conditions (light, dark or random phase) *p<0.05; ***p<0.001; NS, 
not significant. Data are presented as the mean ± s.e.m.
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Figure 6. Optogenetic activation of dmPFC astrocytes elicits a synaptic input 
increase. a, Representative traces of mEPSC events. b, Number of mESPC (Left) 
and sEPSC (Right) events per 10 sec time bin, before, during and after astrocyte 
stimulation (1 min of 20-Hz) (mEPSC: 10 cells from 3 GFAP-mCherry mice and 
11 cells from 3 GFAP-ChR2 mice; sEPSC: 23 cells from 5 GFAP-mCherry mice 
and 17 cells from 4 GFAP-ChR2 mice). Wilcoxon signed-rank test. c and d, 
Cumulative probabilities and mean results of both amplitude and frequency of 
mEPSC (c) and sEPSC (d) (mEPSC: 10 cells from 3 GFAP-ChR2 mice; sEPSC: 17 
cells from 4 GFAP-ChR2 mice). EPSC frequency, not amplitude, increase was 
observed in both mEPSC and sEPSC upon light stimulation. Two-tailed Mann-
Whitney U-test. *p<0.05; ***p<0.001; NS, not significant. Data are presented as 
the mean ± s.e.m. 
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Figure 7. Optogenetic activation of dmPFC astrocytes does not affect neuronal 
excitability. a, Representative traces of excitability of GFAP-mCherry and GFAP-
ChR2. b Number of action potentials at different current steps of GFAP-mCherry 
(9 cells from 3 mice) and GFAP-ChR2 (17 cells from 4 mice). Paired t-test. c, The 
minimal injected current to induce action potential from resting and light-
stimulated pyramidal neurons of GFAP-mCherry and GFAP-ChR2; Paired t-test. 
NS, not significant. Data are presented as the mean ± s.e.m.
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Figure 8. Aggressive behaviors are not affected by optogenetic dmPFC 
astrocyte stimulation. a, Schematic illustration of the resident-intruder test. Both 
male and female mice were housed together for 3-4 weeks. On the day of the test, 
the female mouse was removed and a new male mouse was introduced into the 
cage as an intruder. The behavior test was conducted for 10 min with light 
stimulation (473-nm, 20-Hz) during the experimental period (3 days). The 
behaviors were videotaped, and aggressive behaviors of resident mice were 
measured by counting their (i) chasing duration, (ii) attack duration, and (iii) attack 
frequency for 3 consecutive experimental days. b, Diagram of resident-intruder test 
results divided by aggressive (62.1 %) and non-aggressive resident mice (37.9 %). 
c and d, Mean results of chasing, attack duration, and attack frequency of (Top row) 
non-aggressive resident mice and (Bottom row) aggressive resident mice with light 
stimulation. Both attack duration and frequency increased daily in aggressive 
resident mice with repeated exposure to an intruder, however, the differences 
between the two groups (GFAP-mCherry vs. GFAP-ChR2) were not significant. 
Two-tailed Student’s t-test. NS, not significant. Data are presented as the mean ± 
s.e.m.
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Figure 9. Optogenetic dmPFC astrocyte activation in the dmPFC region does 
not alter locomotion, anxiety, or depressive-like behavior. a, A result of mouse 
locomotion from OFT with intermittent light stimulation during a 10 min 
experimental period. b, (Left) Representative traces of mouse locomotion for 10 
min and (Middle and Right) total distance traveled per 1 min with light on and off. 
c, Distance in center area with intermittent light stimulation during the 10 min 
experimental period. d, Distance traveled in the center per 1 min with light on and 
off during the test session. e, Difference in locomotion speed before and after the 
light stimulation. f, Schematic illustration of EPM with light stimulation. Light was 
delivered during experimental session (5 min) to test mice. g, Anxiety-like 
behaviors assessed by time spent in open and closed arms. h, Depressive-like 
behavior measured by immobility time in the FST (n=6 in each group). Light was 
delivered during experimental session (5 min) to test mice. Two-tailed Student’s t-
test. NS, not significant. Data are presented as the mean ± s.e.m.
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Figure 10. dmPFC astrocyte stimulation induces glutamate release. a, D-serine, 
ATP, and glutamate concentration in dmPFC slice via optogenetic stimulation of 
astrocytes in the dmPFC. (n=3 in each group). b, Extracellular glutamate
concentration by in vivo microdialysis via optogenetic stimulation of astrocytes in 
the dmPFC (n=3 in each group). Paired t-test. **p < 0.01; NS, not significant. Data 
are presented as the mean ± s.e.m.
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Figure 11. Optogenetic stimulation of dmPFC astrocyte modulates social 
hierarchy through AMPA receptor activation. a, (Left) Representative mEPSC 
traces from dmPFC layer V pyramidal neurons. (Middle and Right) Average 
mEPSC amplitude and frequency results after tube test with optogenetic 
stimulation of rank-4 mice (18 cells from 3 rank-1 mice, 15 cells from 3 rank-4 
mice, 11 cells from 3 AAVDJ-GFAP-mCherry-injected rank-4 mice, and 13 cells 
from 3 AAVDJ-GFAP-ChR2-mCherry-injected rank-4 mice). One-way ANOVA, 
Bonferroni post-hoc analysis. b, Biotinylation assays of surface GluA1 and GluA2 
from dmPFC tissue and averaged results (n=7 for rank-1, AAVDJ-GFAP-mCherry-
injected rank-4, and AAVDJ-GFAP-ChR2-mCherry-injected rank-4 mice, and n=6 
for rank-4 mice). One-way ANOVA, Bonferroni post-hoc analysis. *p < 0.05 and 
**p < 0.01 compared to rank-1; # p<0.05 and ## p<0.01 compared to rank-4 of 
GFAP-ChR2. NS, not significant. Data are presented as the mean ± s.e.m.
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Figure 12. AMPA receptor antagonist, NBQX, does not induce hierarchical 
rank elevation of rank-4 mice. a, Schematic illustration of simultaneous 
implantation of both optic fiber and guide cannula in the PL region of the dmPFC. 
Experimental paradigm of NBQX or vehicle treatment 30 min before the tube test 
with or without light stimulation, as outlined by dashed line. b, The result of 
hierarchical rank changes by astrocyte stimulation following treatment with NBQX 
(blue, n=8) or vehicle (black, n=5) 30 min before light stimulation to rank-4 mice. 
Wilcoxon signed-rank test. *p < 0.05; NS, not significant. Data are presented as the 
mean ± s.e.m.
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Figure 13. NBQX pretreatment in the dmPFC region does not alter 
locomotion, anxiety, or depressive-like behavior. a, A result of mouse 
locomotion from OFT (10 min). (Left) Representative traces of mouse locomotion, 
(Middle) total distance traveled, (Right) time in center area during the test session 
(5 min). b, Anxiety-like behaviors assessed by time spent in (Left) open and (Right) 
closed arms by EPM. c, Depressive-like behavior was measured by time 
immobility in the FST. All behavioral tests in were performed 30 min after 
treatment with vehicle or NBQX (n=6 in each group). Two-tailed Student’s t-test. 
NS, not significant. Data are presented as the mean ± s.e.m.
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Figure. 14. Astrocytes and neurons in dmPFC employ distinct behavioral 
strategies to achieve dominancy during tube test. a, Schematic illustrations of 
the tube test procedures. Mice were divided into two groups: one with neuronal 
ChR2 expression by AAVDJ-hSyn1-ChR2-mCherry injection (hSyn1-ChR2 mice) 
and another with astrocytic ChR2 expression by AAVDJ-GFAP-ChR2-mCherry 
injection (GFAP-ChR2 mice) in the dmPFC area. Upon light stimulation during the 
tube test, the average rank change of rank-4 mice was comparable between these 
two groups. GFAP-ChR2 mice did not exhibit elevated pushing behavior, although 
the level of rank induction was similar to those of hSyn1-ChR2 mice. Wilcoxon 
signed-rank test and Student’s two-tailed t-test. b, Schematic illustration of 
dominance competition between light-induced ChR2 injected mice (n=10 for 
GFAP-ChR2 and hSyn1-ChR2) and their matched control mice (n=10 for GFAP-
mCherry and hSyn1-mCherry). Both groups showed comparable winning rates in 
the tube test against control mice. Student’s two-tailed t-test. c, Schematic 
illustration of dominance competition between light-stimulated GFAP-ChR2 and 
hSyn1-ChR2 mice (n=13 in each group). The winning rate between the two groups 
was not different; the winning rate of neuronal ChR2-stimulated mice was 53.8% 
and that of astrocyte ChR2-stimulated mice was 46.2%. **p < 0.01; NS, not 
significant. Data are presented as the mean ± s.e.m.
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Figure 15. Graphical summary of the study. dmPFC astrocyte activation
increases extracellular glutamate, and dmPFC layer V pyramidal neurons receive 
glutamatergic excitatory synaptic inputs. This induces mouse resistance behavior 
during social fight, and results in winning.
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Discussion
These results demonstrate that optogenetic activation of dmPFC 
astrocytes induces winning in social competition and its maintenance via increasing 
resistance behavior. As an underlying mechanism, I discovered that astrocyte 
activation induced prolonged enhancement of excitatory synaptic inputs to dmPFC 
layer V pyramidal neurons without affecting excitability. Therefore, I propose that 
such synaptic potentiation by astrocyte activation induces long-term winning 
during social competition (Fig. 15).
Of note, my data show that astrocytes play a distinct role in social 
dominance behavior compared to neurons. Optogenetic astrocyte stimulation 
elevated mouse social hierarchy in tube tests via a different behavioral strategy 
compared to neuronal stimulation. Optogenetic stimulation of dmPFC pyramidal 
neurons elevated mouse social hierarchy by increasing both pushing and resisting 
behaviors during fights (Fig. 14c)14. Since both chemogeneci and optogenetic 
astrocyte stimulation did not increase pushing behavior (Fig. 3c, Fig. 5c, and Fig. 
14c), I expected dmPFC neuron stimulation to confer dominance over astrocyte 
stimulation in the tube test between these two groups. However, unexpectedly, the 
winning rate was similar between the two groups (Fig. 14e and g). This finding 
indicates that resistance behavior is sufficient to assert dominance. According to a 
previous study, increased firing rate in pyramidal neurons in layer V of the dmPFC 
has a strong correlation with both pushing and resisting behavior during the tube 
test, and, as a result, these behavioral strategies lead to winning14. Although the 
higher firing rate or excitability of neurons induces more pushes and resistance 
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actions, our data show that only resistance behavior is elicited by astrocyte activity. 
Optogenetic astrocyte activation did not increase the neuronal excitability, but 
rather increased mEPSC amplitude and frequency, which might underlie the 
differences in behavioral outcome between neural vs. astrocyte stimulation. This 
suggests that increasing neuronal excitability and the strength of synaptic inputs 
into pyramidal neurons can differentially regulate dominance behavior mode 
(offensive pushing behavior vs. defensive resisting behavior). My findings 
concerning the function of dmPFC astrocytes in mouse resistance behavior will 
hopefully help to elucidate the brain functioning mechanisms of human endurance 
and patience in the future.
Studies on the molecular mechanisms indicate that elevated AMPA 
receptor expression levels in the dmPFC pyramidal neurons are responsible for the 
dmPFC synaptic potentiation and the subsequent change in mouse dominance 
behavior. For instance, AMPA receptor upregulation by injection of GluA4-
expressing virus increases social rank in mice13, and a reduction of AMPA 
receptors in neonatal mice by long-term isolation decreases social rank127. It has 
also been reported that phosphorylation of AMPA receptors by stress or 
fluoxetine121 and allosteric modulation of AMPA receptors128 can modulate social 
dominance. Furthermore, one recent study identified that long non-coding RNA 
(lncRNA) directly regulates AMPA receptor expression in dmPFC pyramidal 
neurons and thereby affects mouse dominance behaviors129. In line with these 
reports, our study revealed that dmPFC astrocyte-stimulated rank-4 mice showed 
increased surface GluA1 expression (a subunit of AMPA receptor) comparable to 
that of rank-1 mice. Accordingly, there was an increase in mEPSC amplitude in 
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rank-4 mice who received dmPFC astrocyte stimulation. My findings indicate that 
AMPA receptor expression in dmPFC pyramidal neurons can be modulated not 
only by MD-PFC neural activation, but also by dmPFC astrocyte activation. This 
also suggests that dmPFC astrocyte activation might be involved in the elevated 
AMPA receptor expression by repeated winning, which warrants future 
investigation.
For clear understanding of the role of dmPFC astrocyte in dominance 
behavior, in vivo functions of dmPFC astrocyte is needed to be investigated. First, 
in ex vivo slice electrophysiology experiment, I observed significantly increased 
excitatory synaptic inputs into pyramidal neurons. However, considering that 
reduced activity of inhibitory interneurons in dmPFC results in enhanced mouse 
dominancy108, it should be observed the influences of optogenetic or chemogenetic 
astrocyte activation on not only excitatory functions but also inhibitory synaptic 
properties. Also, measuring a local field potential activity which indicates 
integrated excitatory and inhibitory neuronal activity might be helpful to identify 
the role of astrocyte. Second, although submissive mice showed significantly 
increased resistance behavior (time resisting) by dmPFC astrocyte stimulation in 
this study, however, whether spontaneous dmPFC astrocyte activity is occurred 
when the mice show resistance behavior during tube test is also necessary to be 
investigated. For this, performing in vivo two-photon Ca2+ imaging experiment may 
help to identify the involvement of dmPFC astrocyte cell in resistance behavior 
during the tube test. Taken together, various in vivo experiments must be conducted 
in the future study for clear identification of the role of dmPFC astrocyte in mouse 
dominance behaviors.
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It should be noted that the optogenetic manipulation I employed is not 
physiological astrocyte activation. In particular, a recent study argues that 
optogenetic astrocyte activation may affect excitability of neurons nearby by 
increasing extracellular K+ concentration in striatum region130. Although it is not 
clear how optic stimulation of ChR2-expressing astrocytes affects their physiology, 
I would like to propose that the behavioral and electrophysiological effects of 
optogenetic astrocyte activation in our study are not merely due to elevated 
potassium levels, because I did not observe any alteration in neuronal excitability 
upon optogenetic astrocyte stimulation (Fig. 2c and d). Also, chemogenetic 
astrocyte activation, which is more physiologically relevant, induced comparable 
behavioral and electrophysiological changes. Therefore, I would like to argue that 
the behavioral effects of dmPFC astrocyte stimulation may have physiological 
relevance.
Although patience or endurance is an important behavioral feature 
characterizing one’s personality, no biological mechanisms have been proposed. In 
this regard, my data may shed new light on our understanding of the brain 
functioning mechanisms of patience or delay of gratification. Notably, endurance 
and patience can be important factors in pursuing a dominant status in human 
society. Individuals compete for status not by bullying and intimidating others, but 
by behaving in ways suggesting high levels of endurance and patience within the 
group131. Possibly, my observation of mouse resistance behavior upon dmPFC 
astrocyte stimulation, which was different from neuronal modulation, provides a 
novel and strategic way to solve social and psychological problems related to a 
lower social hierarchy by targeting dmPFC astrocytes.
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Chapter II




Across species, social position in society can have large effects on health 
and diseases. Individuals with low social status are more vulnerable to MDD. 
Studies using postmortem brain of MDD patients have implicated astrocyte cells in 
dmPFC, however, their involvement in affective disorders due to submissiveness 
has not been studied.
Here, I investigated whether chemogenetic dmPFC astrocyte stimulation 
to chronic restraint stress (RS)-induced mice show both increased dominancy and 
amelioration of depressive behavior. After 3 weeks of RS, the mice showed 
depressive-like behavior compared from normal control. Chemogenetic stimulation 
of dmPFC astrocyte activation in RS mice induced winning in social competition in 
tube test by increasing the persistence of defensive behavior such as resistance. 
Furthermore, repetitive winning experience due to chemogenetic dmPFC astrocyte 
stimulation rendered rapid anti-depressant effect to chronic stress-induced 
depressive mice. I also tested whether optogenetic dmPFC pyramidal neuron 
stimulation could also change dominancy and depressive-like behaviors of RS mice, 
however, these mice did not show anti-depressive effect after the tube test, 
although they showed increased dominancy compared from normal mice.
In this chapter, dmPFC astrocyte-stimulated dominance behavior induces 
winning and finally affects depressive behavior of RS mice which is more effective 
than dmPFC pyramidal neuron-stimulation. It may give a clinical implication to 
treat depression due to lower social status in human. 
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More than 300 million people suffer from MDD, and it is the most 
prevalent mental health problem in the current society world-wide. MDD is often 
described as an overwhelming sadness, despair, and helplessness which lasts for 
several months or even years132. Individuals with MDD are at a high risk of suicide, 
with more than 90% of those who die by suicide who have a history of self-harm133.
Due to the debilitating nature of MDD, most research has been focused on the 
identification of its etiology.
Current studies of depression are arguing and largely focusing on the 
identification of novel structures and functions of neural circuits of the brain134. For 
instance, optogenetic activation of dmPFC to dorsal raphe nucleus (DRN) circuit 
improves mouse depressive behaviors135. In this study, the mice showed increased 
kick frequency during forced swim test which is considered as an increased active 
coping behavior. Moreover, activation of serotonergic neurons in DRN which 
projects to somatostatin-expressing neurons in central nucleus of amygdala 
regulates mouse depressive behaviors136. Although these studies provide key neural 
substrates regulating depressive symptom, however, it is long way to go to reach 
clinical applications. Considering that depression is very complex disorder which is 
affected by various environmental or genetic factors, it is crucial to find a clear 
main cause of MDD to improve treatment efficiency.
Chronic stress is one of the main cause of depressive disorder. It affects 
various parts of animal body and causes diverse physiological changes, which are 
manifested in symptoms such as headache, stomachache, heartburn, fatigue, 
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overeating, or undereating137 in humans. Severe and long-lasting adverse effects 
induced by chronic stress result in psychiatric disorder such as MDD137,138. Among 
various types of chronic stresses, in particular, a common factor that is pervasively 
linked to MDD is socio-economic status (SES), with substantial evidence that the 
more disadvantaged are disproportionately affected by mental health problems and 
their consequences. Moreover, SES is currently considered as one of the strongest 
predictors of mortality and mobility in humans, which that low SES is associated 
with higher risk of diseases including cardiovascular disease, cancer, and multiple 
psychiatric conditions139. In particular, MDD has been highly associated with low 
SES even after accounting for life style factors. In addition, individuals with low 
SES are more vulnerable to MDD140,141, for low SES is a kind of chronic stress for 
human. Therefore, comorbidity between low social status (low SES) and 
depression is increasingly recognized.
Although the comorbidity between low social status and depression has 
been provided in human, a link between depressive and submissive behaviors was 
implied by an animal study using selective serotonin reuptake inhibitors (SSRIs)121, 
widely used anti-depressant drugs for MDD. In this study, chronic SSRI 
administration not only reversed depressive behaviors of chronic stress-induced 
mice, but also rescued submissive behaviors121. Notably, chronic SSRI treatment 
rescued the astrocyte cell loss in the dmPFC of the depressive mice58, which is 
often observed in MDD patients142,143. This suggests that dmPFC astrocytes may 
play a role in the psychological influence of social dominance. It is conceivable 
that dmPFC astrocyte may have a key role for the regulation of comorbidity of 
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dominance and depression, however, the role of dmPFC astrocyte in depressive and 
social dominance behaviors have still not been investigated.
Moreover, considering that depression have comorbidity with 
submissiveness144 and submissive mice show depressive behaviors compared from 
dominant mice31, there is no study investigating the possibility of anti-depression 
by dominancy increase. According to the previous report suggesting that repeated 
winning experience induces ‘winner effect’14, it is possible to think that repeated 
experience of winning may positively affect to psychological traits such as 
depressed mood. Because both dmPFC pyramidal neurons and astrocytes are all 
induce winning in the tube test which are shown in chapter I, therefore, performing 
tube test with optogenetic or chemogenetic activation of dmPFC pyramidal neuron 
of astrocytes. Taken together, make submissive mice into dominant is suitable for 
measure anti-depressive effect of chronic stress-induced depressive mice.
In the previous chapter, I revealed that dmPFC astrocyte activation 
induces hierarchical rank elevation of submissive mice. Here, in chapter II, I 
postulated that repetitive winning experience may induce psychological change, 
therefore, I compared depressive-like behavior before and after the winning of 
chronic restraint stressed mice to see whether depressive symptom can be 
ameliorated by changing the behavior mode. Lastly, I quantitatively determined the 





Six to 16-week-old male C57BL/6J mice of similar body weights were used for 
experiments. The animals were housed and maintained in a controlled environment 
at 22-24°C and 55% humidity with 12 h light/dark cycles and fed regular rodent 
chow and tap water ad libitum. All animal care was guided by the Seoul National 
University Institutional Animal Care and Use Committee (SNU IACUC, SNU-
180416-3).
Stereotaxic Viral delivery
Nine to 10-week-old wild type male mice that showed stable hierarchy in cages 
were used for viral delivery. Animals were anesthetized with isoflurane and secured 
in a stereotaxic frame (Stoelting Co., Wood Dale, IL, USA). Holes the size of the 
injection needle were drilled into the skull, and bilateral or unilateral injections 
with 0.7 ml (titer 1013 GC/ml) of AAVDJ or AAV5 were administered in each side. 
The injection syringe (Hamilton Company, Reno, NV, USA) delivered the AAVDJ 
or AAV5 at a constant volume of 0.1 ml/min using a syringe pump (Stoelting Co.). 
The needle was left in place for 3 min after each injection to minimize the upward 
flow of the viral solution after raising the needle. The injection coordinates of the 
PL subregion of the dmPFC were angle: 10°, AP: +2.43, ML: ±0.61, DV: -1.78 
from bregma. Mono fiber-optic cannula were bilaterally implanted 1 week after the 
viral injection, 400 mm above the viral injection site (angle: 10°, AP: +2.43, ML: 
±0.61, DV: -1.38 from bregma). Anchor screws were located in the skull and fixed 
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with Zinc Polycarboxylate dental cement. AAVDJ-GFAP-mCherry, AAVDJ-
CamKII-eGFP and AAVDJ-CamKII-ChR2-eGFP were purchased from the Korea 
Institute of Science and Technology (KIST, Seoul, Korea), and pXac2.1-
gfaABC1D-hM3Dq-mCherry plasmid was purchased from Addgene (#92284, 
Watertown, MA, USA) and packaged in AAV5 by Upenn Vector Core 
(Philadelphia, PA, USA). Animals injected with virus were used for assessments of 
behaviors 2-3 weeks after the injection. Animals injected with AAVDJ or AAV5 but 
showing no detectable viral expression in the target region were excluded from the 
analyses.
Chronic restraint stress
Mice were individually placed into 50 ml polypropylene conical tubes with a nose-
hole for ventilation, and were exposed to restraint stress (3 h/day) for 14 
consecutive days. After restraint stress, mice were returned to the home cage. One 
day after the last restraint stress, mice were weighed and used for further 
experiments.
Behavioral studies
On the day of all behavioral testing, animals were moved to the test room and left 
to habituate for at least 1 h. The light condition of the test room was maintained at 
the same intensity (100 lux) as the animal rooms under daylight conditions.
Tube test. We used a transparent Plexiglas tube with 30 cm length and 3 cm inner 
diameter. Six-week-old male mice were housed in groups of 4 for at least 2 weeks 
before tube test. Before the main test, each mouse was trained to go through the 
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tube for 10 trials in two consecutive days. On the test day, pairs of mice were 
released into the opposite ends and met at the middle of the tube. The tube test was 
performed for 2 min. If no winner or loser was decided within 2 min, the test was 
repeated. Between each trial, the tube was cleaned with 70% ethanol. Within each 
cage of four pairs, mice were randomly assigned such that each mouse would meet 
every other mouse of the group only once, resulting in six matches per cage. All 6 
pairs of mice were tested daily with a round robin design and ranks were 
determined by total number of wins. Only cage mates that maintained stable ranks 
for at least 3 or 4 days were used for further experiments. The behaviors were 
videotaped and both push and resistance behaviors were counted. 
Tube test with chemogenetic astrocyte stimulation and optogenetic pyramidal 
neuron stimulation. After 2 days of tube training, CNO (3 or 6 mg/kg) was 
intraperitoneally injected to hM3-expressing mice. Then we performed tube test at 
30 min, 2, 6, and 24 h after the injection. Identically, optogenetic stimulation (473 
nm, 100 Hz, 1 ms of pulse duration) was delivered to ChR2-expressing mice. 
Dominance competition between the mice groups (No stress vs. Stress). Each test 
mouse was matched 4 times against different group mice. The winning rate of each 
test mouse was calculated by counting total number of wins. 
OFT. The apparatus consisted of a brightly illuminated 40 cm x 40 cm square arena 
surrounded by a 40 cm high wall. Mice were individually placed in the center of 
the arena, and their locomotion activity was monitored by an automatic system for 
10 min. Light stimulation of 473 nm was intermittently turned on and off on the 
test mice (GFAP-ChR2 mice and GFAP-mCherry mice) with 1 min intervals. Total 
distance and time spent in the center zone per minute were analyzed by automated 
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video tracking system (SMART, Panlab SL, Barcelona, Spain). The activity 
chamber was cleaned with 70% ethanol after each use to eliminate any olfactory 
cues from the previously tested mouse.
FST and TST. We conducted forced swim tests by placing each animal 
individually in transparent cylinders filled with water (23-25°C; depth 15 cm) for 5 
min. Immobility in the FST was defined as the state in which mice were judged to 
be making only the movements necessary to keep their head above the surface. The 
TST was performed by hanging each animal from the top of a square box for 5 min. 
For optogenetic astrocyte stimulation in FST, light was delivered during the whole 
experimental session to GFAP-ChR2 mice and their control group. Both trials were 
videotaped and immobility time was analyzed using a video tracking system.
Experimental protocols including OFT, FST, and TST were designed to take into 
account potential stress that could affect test mice behavior. Behavioral assessment 
was performed in the following sequential order to minimize stress effects: OFT, 
EPM, FST, and TST. 
Pearson’s correlation and K-means classification
K-means clustering analysis is one of the simplest and most popular unsupervised 
machine learning algorithms. It aims to separate scattered data into k clusters in 
which each data point belongs to the cluster with the nearest mean (centroid). This 
method has been successfully employed in various biological fields to identify and 
classify complex biological features145-148.
We plotted individual mouse immobility values into a 2-dimentional space by 
defining Mn (t
FST, tTST), in which M means mouse and n indicates the mouse number. 
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We first performed a Pearson’s correlation analysis to verify whether the 
immobility values in the FST and TST correlated with each other. The FST 
immobility values of 56 mice, including all non-RS (n=28) and RS (n=28) mice, 
showed a significant positive correlation with the TST immobility values. We 
performed a K-means classification analysis to divide the immobility values into 
two groups (k=2). Classification was started from two random points for every 
cluster, and we performed 1000 iterative calculations to optimize the positions of 
the centroids in each cluster. After 1000 iterations, the centroids of each classified 
cluster were determined, and we compared the centroids with the values measured 
from experiments. Centroids of each classified group were similar to experimental 
values, and we then verified classification accuracy. The data were classified into 
‘Normal’ and ‘Depressed’ groups with 91.1% classification accuracy. Among the 
28 non-RS mice, 25 were correctly classified as “Normal” and 3 were incorrectly 
classified as “Depressed” (89.3% classification accuracy). Among the 28 RS mice, 
26 were correctly classified as “Depressed” and 2 mice were incorrectly classified 
as “Normal” (92.9% classification accuracy). Next, we performed K-means 
classification using the FST and TST immobility values obtained from the non-RS 
and RS mice after tube testing. The k value was again 2, and the classification 
iteration was 1000. Both Pearson’s correlation and K-means classification analyses 
were performed in MATLAB (R2019a).
Statistics
Satistical significance was determined using the two-tailed Student’s t-test, paired 
t-test, Wilcoxon signed-rank test, or two-tailed Mann-Whitney U-test for 
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comparison between two groups. For multiple comparisons, one-way ANOVA and 
Bonferroni’s multiple comparison tests were used. All data are represented as the 
mean ± s.e.m., and differences were considered statistically significant when the p-
value was less than 0.05.
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Results
Dominancy is related with depression. 
Studies indicate a correlation between one’s social status and 
susceptibility to depression20,23,149. Many studies show that chronic RS-induced 
depressive mice (RS mice) develop submissive behavior31,121,150-152, and these 
behavioral phenotypes, i.e., depressive and submissive behaviors, are both rescued 
by chronic treatment with anti-depressants such as fluoxetine31,121,152. Considering 
the frequent comorbidity of submissiveness and depression, we explored whether 
the dmPFC astrocyte- or neuron-activated dominance behavior could affect RS-
induced depressive-like behavior. We designed a behavioral paradigm to assess 
whether allowing tube test winning experiences by chemogenetic astrocyte (Fig. 
1a) or optogenetic pyramidal neuron (Fig. 1b) activation in dmPFC could render 
anti-depressive effects to the RS mice. Mice were injected with gfaABC1D-
hM3Dq (Fig. 1a, RS mice) or CamKII-ChR2 (Fig. 1b, RS mice) virus into the right 
PL region for chemogenetic astrocyte and optogenetic neuron stimulation, 
respectively. We adopted a chemogenetic astrocyte activation method for these 
experiments since it is more physiologically relevant than optogenetic activation. 
For the control, mice were injected with AAV5-gfaABC1D-mCherry or AAVDJ-
CamKII-eGFP, and these control mice were not subjected to RS (non-RS mice). 
After 3 weeks of daily RS, mice were assessed for depressive-like behaviors in the 
OFT, FST, and TST (indicated as ‘Pre-tests’ in Fig. 1a and b). Following two 
consecutive days of tube training and a tube test (basal test), mice were subjected 
to tube tests with chemogenetic astrocyte stimulation with CNO injection (day 42–
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43 in Fig. 1a) or optogenetic neuron stimulation (day 49–53 in Fig. 1b). All 
experimental mice were then re-assessed in the FST, TST, and OFT (indicated as 
‘Post-tests’ in Fig. 1a and b). 
Astrocyte stimulation-induced winning experiences render a rapid anti-
depressive effect. 
In the Pre-tests, RS mice exhibited levels of locomotive activity 
comparable to non-RS control mice (Fig. 2a). However, they showed significantly 
increased immobility in the FST and TST (Fig. 2b and c) compared with non-RS 
mice, indicating development of depressive-like behavior upon 3 weeks of daily 
RS. The day after the TST, we performed tube test training and a basal tube test to 
measure relative dominance between the two groups (‘RS’ vs. ‘non-RS’). In this 
basal tube test, the non-RS mice had a higher winning rate than the RS mice and 
exhibited greater pushing and resistance behaviors (Fig. 3a-c, and Fig. 4a-c). On 
the following day, we performed the tube test again after dmPFC astrocyte 
stimulation via CNO injection (i.p., 6 mg/kg). Upon chemogenetic dmPFC 
astrocyte stimulation, the RS mice showed dramatically elevated resistance 
behavior both at 2 and 6 h, which increased their winning rates against the CNO-
injected non-RS control mice (Fig. 3b and c). Of interest, after 24 h, the astrocyte-
activated RS mice increased pushing behavior as well (Fig. 3a). At 6 and 24 h after 
CNO injection, the winning rate of the RS mice was higher than that of the non-RS 
mice (Fig. 3c). Meanwhile, optogenetic stimulation of dmPFC neuron in RS mice 
rendered different behavioral outcomes. Contrary to astrocyte stimulation, dmPFC 
pyramidal neuron-stimulated RS mice did not win out over the light-stimulated 
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non-RS control mice, although both pushing and resisting times gradually 
increased by repeated tube tests (Fig. 4). The neuron-stimulated RS mice exhibited 
a winning rate comparable to non-RS mice only after 3 days (Fig. 4c). 
After tube tests, we repeated the FST, TST, and OFT (‘Post-tests’). 
Locomotive behavior was not affected by winning experiences in both dmPFC 
astrocyte- and pyramidal neuron-stimulated RS mice (Fig. 5a).  In RS mice who 
obtained tube test winning experiences by dmPFC astrocyte activation, the 
depressive behaviors observed in the ‘Pre-tests’ were almost completely abrogated 
(Fig. 5b and c). However, RS mice who increased their winning rate by optogenetic 
dmPFC pyramidal neuron stimulation still showed higher immobility in the FST 
and TST during ‘Post-tests’ compared to non-RS controls (Fig. 5a-c). These data 
indicate that dmPFC astrocyte activation, but not neuron stimulation, renders anti-
depressive effects to RS mice. 
Acute chemogenetic astrocyte stimulation does not affect depressive behaviors 
of RS mice.
To test the relationship between winning experience acquisition and anti-
depressive effects by dmPFC astrocyte activation, we subjected the gfaABC1D-
hM3Dq virus- or GFAP-mCherry virus-injected mice to the same experimental 
scheme except for the tube tests (Fig. 6a). Notably, chemogenetic dmPFC astrocyte 
stimulation per se, without tube test winning experiences, did not induce anti-
depressive effects in RS mice (Fig. 6b-e), indicating that tube test winning 
experiences are required for the dmPFC astrocyte-derived anti-depressive effects. 
In line with this, acute chemogenetic dmPFC astrocyte stimulation did not deter the 
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RS mice from manifesting depressive-like behavior in the FST compared with non-
RS control mice (Fig. 7). 
K-means clustering analysis confirms the anti-depressive effects of dmPFC 
astrocyte-derived winning experiences.
To quantitatively determine the development of depressive-like 
phenotypes of RS mice after winning, I performed a K-means clustering analysis, a 
widely used mathematical analysis to categorize complex data sets into various 
subgroups153,154 (Fig. 8a). K-means clustering analysis is one of the simplest and 
most popular unsupervised machine learning algorithms. It aims to separate 
scattered data into k clusters in which each data point belongs to the cluster with 
the nearest mean (centroid). This method has been successfully employed in 
various biological fields to identify and classify complex biological features145-148.
I performed K-means clustering analysis to classify the values into two 
groups, ‘Normal’ and ‘Depressed’. The K-means clustering algorithm successfully 
classified the FST and TST values from non-RS mice and RS mice with 89.3% and 
92.9% classification accuracy, respectively (Fig. 8b). Only three of 28 non-RS 
mice and two out of 28 RS mice were incorrectly classified as ‘Depressed’ and 
‘Normal’, respectively (Fig. 8b). Combining the values of both non-RS and RS 
mice together, the classification accuracy was 91.1% (Fig. 8c). The centroids of 
each group (‘Normal’ or ‘Depressed’) were similar to the mean immobility time of 
non-RS and RS mice (Fig. 8d).
I plotted all immobility values from ‘Pre- tests’ of FSTs and TSTs of all tested mice 
and found a significant positive correlation of immobility time between the FST 
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and TST (R2=0.4073) (Fig. 9a). Individual data clearly show that mice with high 
immobility in the FST also exhibit high immobility in the TST (Fig. 9a). I then 
analyzed immobility data of the FST and TST from ‘Post-tests’ of RS mice. The 
results showed that all RS mice who obtained winning experiences by dmPFC 
astrocyte stimulation were classified ‘Normal’ (Fig. 9b). In contrast, only one RS 
mouse with dmPFC pyramidal neuron stimulation was classified as ‘Normal’ 
(14.3%), while 7 out of 8 mice were still classified as ‘Depressed’ (85.7%) (Fig. 
10). Taken together, these results confirm the anti-depressive effects of dmPFC 
astrocyte-stimulated winning experiences and demonstrate that tube test winning 
from targeting dmPFC astrocytes renders more effective anti-depressive effects 
than targeting dmPFC pyramidal neurons (Fig. 11).
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Figure 1. Experimental schemes to measure winning-induced anti-depressive 
effect. a, Behavioral experimental scheme targeting dmPFC astrocytes. The 
experimental schemes were designed to compare depressive behaviors of RS mice 
before and after the tube test. Two weeks after virus injection (n=12 for AAVDJ-
GFAP-mCherry in ‘non-RS’ mice and n=12 for AAV5-gfaABC1D-hM3Dq-
mCherry in ‘RS’ mice), 3 hours of daily restraint stress was delivered to RS mice 
for 3 weeks. The day after the last restraint stress, the OFT, FST, and TST 
(indicated as ‘Pre-tests’) were performed for 3 consecutive days. Following 2 days 
of tube training, mice were subjected to a basal tube test and then a tube test 
following CNO treatment (2, 6, and 24 h after CNO injection). After the last day of 
the tube test, the FST, TST, and OFT were performed again (indicated as ‘Post-
tests’). b, Behavioral experimental scheme targeting dmPFC pyramidal neurons. 
Two weeks after virus injection (n=8 for AAVDJ-CamKII-eGFP in ‘non-RS’ mice 
and n=8 for AAVDJ-CamKII-ChR2-eGFP in ‘RS’ mice), restraint stress was 
delivered to RS mice for 3 weeks. After the last day of restraint stress, optic fiber 
was implanted in all mice. One week later, the groups were given ‘Pre-tests’ (OFT, 
FST, and TST). Following 2 days of tube training, mice were subjected to tube tests 
with light stimulation. Then, the groups were given ‘Post-tests’ (FST, TST, and 
OFT).
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Figure 2. Chronic restraint stress induces increased depressive-like behaviors. 
a, Traces of locomotion, total distance traveled, and time in center in OFT. 
Student’s t-test. b, Time immobility in FST. Student’s t-test. c, Time immobility in 
TST. Student’s t-test. *p<0.05; **p<0.01; ***p<0.001; NS, not significant. Data 
are presented as the mean ± s.e.m.
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Figure 3. Behavioral mode shifts of RS mice by dmPFC astrocyte activation. a 
and b, Comparison of pushing and resistance of ‘non-RS’ and ‘RS’ mice during the 
tube competition before and after CNO injection (6 mg/kg, i.p.). Student’s t-test. c, 
Percent of winning between ‘non-RS’ and ‘RS’ mice before and after CNO 
injection. Paired t-test. *p<0.05; **p<0.01; NS, not significant. Data are presented 
as the mean ± s.e.m.
７９
Figure 4. Behavioral mode shifts of RS mice by dmPFC pyramidal neuron-
activation. a and b, Comparison of pushing and resistance of ‘non-RS’ and ‘RS’ 
mice during the tube competition before and after light stimulation (473 nm, 100 
Hz). Student’s t-test. c, Percent of winning between ‘non-RS’ and ‘RS’ mice before 
and after light stimulation. Paired t-test. *p<0.05; **p<0.01; ***p<0.001; NS, not 
significant. Data are presented as the mean ± s.e.m.
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Figure 5. Winning experience with resistant behavioral strategy in the tube 
competition has a rapid anti-depressant-like effect on chronic restraint stress-
induced depression. a, Locomotive behaviors of non-RS and RS mice. Student’s t-
test. b, Time immobility from FST after the tube test after the tube test. Student’s t-
test. c, Time immobility from TST after the tube test in experimental set #1. 
Student’s t-test. *p<0.05; **p<0.01; ***p<0.001; NS, not significant. Data are 
presented as the mean ± s.e.m.
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Figure 6. dmPFC astrocyte activation-derived anti-depressive-like behaviors 
were not observed in the absence of tube test winning experiences. a, 
Experimental scheme to measure the effects of tube test winning experience on the 
anti-depressive-like behaviors shown in the dmPFC astrocyte-activated RS mice. 
RS mice were subjected to the same experimental procedures as Figure 5a, but 
without tube tests. b and c, Depressive-like behaviors of RS and non-RS mice were 
measured by comparing ‘Pre-tests’ (FST at day 37 and TST at day 38) and ‘Post-
tests’ (FST at day 44 and TST at day 45). RS mice showed higher immobility times 
than non-RS control mice before and after CNO injection (6 mg/kg, i.p.). Student’s 
t-test. d and e, Mouse locomotion measured by OFT before (Pre-test at day 36) and 
after (Post-test at day 46) CNO injection. Student’s t-test. *p < 0.05; ***p<0.001; 
NS, not significant. Data are presented as mean ± s.e.m.
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Figure 7. Acute dmPFC astrocyte activation does not induce anti-depressant 
effect. a, Experimental scheme to measure anti-depressive behavior of RS mice 
after acute CNO injection. AAVDJ-GFAP-mCherry or AAV5-gfaABC1D-hM3Dq-
mCherry virus was injected into dmPFC (day 0). After 3 weeks RS, OFT and FST 
were performed to measure basal locomotion (day 36) and depressive behavior
(day 37). At day 38, FST was performed again at 2 and 6 h after the CNO injection 
(6 mg/kg). b, The result of (Right) total distance and (Left) time in center from OFT. 
c, Time immobility measured by FST at basal, and 2 and 6 h after CNO injection. 
Student’s t-test. *p < 0.05; **p < 0.01; NS, not significant. Data are presented as 
the mean ± s.e.m.
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Figure 8. Astrocyte-derived winning experience has a 75% of anti-depressant 
effect in RS mice. a, Scheme of K-means clustering analysis. RS mice, which 
show both submissive and depressive phenotypes, were subjected to repeated tube 
tests with dmPFC astrocyte- or neuron-stimulation, allowing winning experiences. 
The immobility times in the FST and TST before (‘Pre-tests’) and after (‘Post-
tests’) the tube tests were collected and analyzed by K-means clustering analysis. b, 
The data were clustered into 2 groups, ‘Normal’ and ‘Depressed’. The immobility 
time values from Pre-tests (FST and TST) of non-RS and RS mice were used to 
classify the data into two groups. (n=28, data from Experiments in Figure 5a and b, 
and Supplemental Fig. 5c). Among 28 non-RS mice, 25 out of 28 mice were 
classified as ‘Normal’, and 3 out of 28 mice were classified as ‘Depressed’ 
(Classification accuracy = 89.3%). Among 28 RS mice, 26 out of 28 mice were 
classified as ‘Depressed’ and 2 mice were classified as ‘Normal’ (classification 
accuracy = 92.9 %). c, Combining both non-RS and RS mice, K-means clustering 
method classified the behavior data with 91.1% accuracy. Only 5 out of 56 mice 
were incorrectly classified (error rate = 8.9%). d, Centroids of each classified 
cluster were similar to the mean values of immobility measured from experiments.
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Figure 9. Behaviors of RS mice after repetitive winning are classified as non-
RS-like behaviors by the K-means clustering analysis. a, Pearson’s correlation 
analysis shows that the immobility values between the FST (n=28) and TST (n=28) 
show significant positive correlation (R2=0.4073). The result of K-means clustering 
analysis classified the values into two groups (green: ‘Normal’, and blue: 
‘Depressed’). b, Individual scatter plots of immobility times of non-RS and RS 
mice measured from the FST and TST after tube tests. These scatter plots clearly 
show that immobility times from the FST and TST of astrocyte-stimulated RS mice 
are classified in the ‘Normal’ cluster; however, the data of neuron-stimulated RS 
mice are still classified in the ‘Depressed’ cluster.
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Figure 10. Astrocyte-induced winning renders rapid anti-depression. a, Results 
of the K-means clustering of RS mice who obtained winning experiences upon 
dmPFC astrocyte- or pyramidal neuron-stimulation. In astrocyte-stimulated RS 
mice, all 12 mice were classified as ‘Normal’. In dmPFC pyramidal neuron-
stimulated RS mice, only 1 of 8 mice was classified as ‘Normal’, and 7 mice were 
classified as ‘Depressed’. b, Comparison of the percentages of classification of RS 
mice after winning experiences. Astrocyte-targeted RS mice were all classified as 
‘Normal’ (100%; 12 out of 12) after tube tests. Pyramidal neuron-targeted RS mice 
were classified as ‘Normal’ (14.3%; 1 out of 8) or ‘Depressed’ (85.7%; 7 out of 8) 
after tube tests.
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Figure 11. Graphical summary. Chronic restraint stress received mice show 
depressive-like behaviors. dmPFC astrocyte or pyramidal neuron stimulation of 
these mice induces resistance or pushing behavior respectively during the tube test, 
and it results in the winning against normal mice. dmPFC pyramidal neuron-
stimulated stressed mice still show depressive phenotypes although they 
experienced winning. However, repeated winning experience of stressed mice by 
dmPFC astrocyte-stimulation show rapid anti-depressive behaviors.
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Discussion
In this study, I uncovered a novel role of dmPFC astrocytes in controlling 
mouse dominance behavior, and subsequently a depressive behavior. I observed 
rapid anti-depressive effects by astrocyte-derived winning experience. In this study, 
the ‘RS’ mice started to win by resistance behavior, however, they showed 
significantly elevated pushing action at 24 h after the CNO injection. This 
behavioral shift may be due to the prior winning experience obtained by resistance 
action (2 and 6 h), which might confer a winning effect.
A causal relationship between low social status and depression has been 
proposed in clinical studies25,152, yet it had not been investigated in animals. In this 
study, we failed to observe statistically significant depressive-like behavior in rank-
4 mice compared to rank-1 mice (Fig. 5a). Therefore, as an alternative, we adopted 
an RS mouse model that showed both depressive and submissive behaviors to 
study the putative relationship between these two behaviors. First, we tested 
whether dmPFC astrocyte or neuron stimulation induces dominant behavior in the 
RS-induced depressive mice. As with un-stressed normal mice, dmPFC astrocyte 
stimulation increased resistance behavior of RS mice in tube test, while dmPFC 
neuronal stimulation increased both pushing and resistance behaviors. Of interest, 
upon repeated tube competition, chemogenetic activation of dmPFC astrocytes in 
RS mice elicited a dramatic behavioral mode change (from defensive resisting to 
offensive pushing) and reversed the final winning odds against non-RS control 
mice within a day. In contrast, optogenetic stimulation of dmPFC pyramidal 
neurons in RS mice caused a gradual increase of both pushing and resistance 
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behaviors but failed to reverse the final winning odds against non-RS mice even 
after five days. These data suggest that dmPFC astrocyte stimulation exerts more 
potent dominance-enhancing effects in depressed mice than dmPFC pyramidal 
neuron stimulation. 
The most important finding of our study is that dmPFC astrocyte 
stimulation induced rapid and strong anti-depressive effects in RS mice. What is 
intriguing is that such astrocyte stimulation-derived anti-depressive effects were 
not observed in the absence of tube test winning. This indicates that dmPFC 
astrocyte activation per se is not sufficient, but rather winning experiences in the 
tube test are required for the anti-depressive effects. It has been proposed that 
repetitive winning experiences induce ‘winning memory’ and often result in 
‘winner effect’155. Although purely speculative, it can be conceived that repeated 
tube test winning experiences aided by dmPFC astrocyte stimulation helped to 
form ‘winning memory’ in the RS mice, which changed their depressive behavioral 
mode. 
It needs to be noted that, contrary to astrocyte stimulation, optogenetic 
dmPFC pyramidal neuron stimulation failed to induce anti-depressive effects in RS 
mice, even though it increased the winning rate of RS mice to a level similar to that 
of non-RS mice after five days of consecutive tube tests. This might be simply 
because the final winning rate of these mice was not high enough to induce anti-
depressive effects; dmPFC astrocyte-stimulated RS mice won out over non-RS 
mice in the tube tests, but neuron-stimulated RS mice did not. It is also possible 
that more than tube test winning is needed for the dmPFC astrocyte stimulation to 
induce anti-depressive effects. It is conceivable that dmPFC astrocyte activation 
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also has an influence on the function of other dmPFC neurons besides pyramidal 
neurons, which is required for the anti-depressive effects. Indeed, it has been 
reported that prefrontal inhibitory GABAergic neurons affect both mouse 
dominance108 and depressive behavior156,157. In this regard, it will be of interest to 
test if dmPFC astrocyte activation also affects GABAergic neuron activity.
Self-awareness of submissiveness might be a key feature affecting depressive 
mood in subordinate subjects, which are often managed by cognitive behavior-
based therapy (CBT) for depression158,159. Our data of the unexpected roles of 
dmPFC astrocytes in dominant and anti-depressive behaviors might lead to the 
elucidation of the biological basis of CBT for depression. It also needs to be noted 
that the anti-depressive behavior manifested within a day of astrocyte-stimulated 
tube test winning. Such a rapid anti-depressant effect from dmPFC astrocyte-
derived winning experiences is quite remarkable considering that even SSRIs, 
traditional anti-depressant drugs, require several weeks or even months to exert 
their anti-depressive effects. Furthermore, considering the prevalent side effects of 
traditional anti-depressant drugs89,160, this astrocyte activation-induced behavioral 
approach may be a much more efficient strategy for depression treatment. Although 
the precise cellular and molecular mechanisms underlying the anti-depressive 
effects of astrocyte-stimulated winning experiences remain elusive, our results 




In this study, I revealed that dmPFC astrocytes induce winning in 
submissive mice by resistance behavior during tube test, and this behavioral mode 
shift reduces depressive-like phenotype of stress-induced depressive mice.
In chapter I, I chemogenetically and optogenetically stimulated dmPFC 
astrocyte of submissive mice which previously showed repeated losing. However, 
after dmPFC astrocyte stimulation, the mice showed increased resistant action. 
This dmPFC astrocyte-derived dominance behavior induced winning of submissive 
mice. As a mechanism, dmPFC astrocyte stimulation increased extracellular 
glutamate, and it showed correlation with AMPA receptor-mediated excitatory 
synaptic input. These results suggest that dmPFC astrocytes play crucial role for 
social winning by showing persistence of resistance behavior.
In chapter II, I revealed behavior-based treatment of depression. I 
introduced depressive mouse model by giving a chronic restraint stress. All stressed 
mice showed both depressive and submissive behaviors compared from their 
control mice. However, after chemogenetic stimulation of dmPFC astrocyte, 
stressed mice showed prolonged winning in tube test even after without dmPFC 
astrocyte stimulation. Behavioral actions were shifted from resistance to pushing. 
Such winning experience successfully reversed the depressive behaviors of stressed 
mice. 
These results suggest that dmPFC astrocyte could be a novel target for the
individual with low social status, and may provide a clinical implication in treating
depression due to low social status.
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국문 초록
사회 서열행동 및 우울증에 미치는 전전두엽 성상교세포의 기능 연구
서울대학교 대학원
치의과학과 신경생물학 전공
노 경  철
사회 서열에 직접적으로 관여하는 서열행동은 대부분의 동물들이 기본
적으로 가지고 있는 본능행동이다. 보다 높은 사회적 위치를 달성하고 이를 유
지하고자 하는 행동은 생존을 위해서 필수적이다. 최근 연구들은 뇌의 전전두엽
영역의 피라미드 신경세포가 높은 사회적 지위에 도달하고 이를 유지하는 데에
직접적인 역할을 한다는 것으로 보고하고 있다. 한편 사회적 서열과 정신 건강
사이에는 깊은 상관 관계가 있는 것으로 알려져 있는데, 낮은 사회 경제적 위치
가 우울증 발병의 많은 원인 중 하나라는 연구 결과가 그 대표적이다. 뇌 전전
두엽 영역의 성상교세포가 항우울제에 대한 반응에 관여하는 핵심세포로 기능
하고 있는 점으로 볼 때, 성상교세포가 서열행동과 더불어 낮은 서열로 인한 우
울증에 동시에 관여할 가능성이 있다. 본 연구에서는 생쥐의 서열행동과 우울증
에 대한 뇌 전전두엽 성상교세포의 역할을 밝히고자 한다.
이 논문의 첫 장에서는 사회적 서열이 낮은 생쥐의 뇌 전전두엽 성상
교세포를 화학 및 광유전학적으로 자극함으로써 성상교세포의 활성이 서열행동
에 미치는 영향을 분석하였다. 전전두엽 성상교세포의 화학 및 광유전학적 자극
은 생쥐의 저항 행동을 유발하였고, 이는 하위 서열에 있는 생쥐의 서열 상승을
크게 유도하였다. 나아가 전전두엽 성상교세포의 광유전학적 활성은 세포 밖 글
루타메이트 농도를 증가 시켰으며, 이는 피라미드 신경세포로 흥분성 시냅스 입
력을 증가시키는 데에 기여하였다. 더불어 서열행동을 유발하는 성상교세포와
신경세포의 차이를 확인하기 위해 성상교세포와 피라미드 신경세포를 광유전학
적으로 각각 자극한 생쥐를 서로 경쟁시켰다. 그 결과 두 생쥐간의 승률은 차이
가 없었지만 승리하기 위한 행동 방식이 서로 다른 것으로 나타났다.
제 2 장에서는 성상교세포 활성에 의해 유발된 서열행동이 항우울 효
과를 보임을 밝혀냈다. 3 주간의 구속 스트레스를 받은 생쥐는 우울 행동을 보
였을 뿐 만 아니라 급격히 저하된 서열행동을 보였다. 그러나 스트레스를 받은
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생쥐의 전전두엽 성상교세포를 화학유전학적 방법으로 자극하면, 자극을 받은
생쥐는 스트레스를 받지 않은 정상 생쥐에 대하여 강한 저항 행동을 보이고, 이
를 통한 반복적인 승리 이후에는 밀어내기 행동을 보였다. 이러한 행동 변화는
만성 스트레스에 의해 유발된 우울 행동을 빠르게 개선시켰는데, 피라미드 신경
세포를 자극하였을 경우에는 항우울 효과가 나타나지 않았다.
본 연구에서는 생쥐의 지속적인 저항 행동으로 인한 경쟁에서의 승리
가 전전두엽의 성상교세포 활성과 직접 관련이 있으며, 빠른 항우울 효과를 보
인다는 것을 밝혀냈다. 이는 낮은 사회적 지위로 인해 발병하게 되는 만성 스트
레스성 우울증에 대해 전전두엽의 성상교세포가 새로운 치료 타겟이 될 수 있
음을 시사한다.
주요어: 서열행동, 성상교세포, 사회 서열, 전전두엽, 우울증, 항우울 효과
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